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A B S T R A C T
Background
’Fast-track surgery’ or ’enhanced recovery protocol’ or ’fast-track rehabilitation’, incorporating one or more elements of preoperative
education, pain relief, early mobilisation, enteral nutrition and growth factors, may improve health-related quality of life and reduce
length of hospital stay and costs. The role of enhanced recovery protocols in major upper gastrointestinal, liver and pancreatic surgery
is unclear.
Objectives
To assess the benefits and harms of enhanced recovery protocols compared with standard care (or usual practice) in major upper
gastrointestinal, liver and pancreatic surgery.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL; Cochrane Library; 2015, Issue 3), MEDLINE, EMBASE
and Science Citation Index Expanded until March 2015 to identify randomised trials. We also searched the references of included trials
to identify further trials.
Selection criteria
We considered only randomised controlled trials (RCTs) performed in people undergoing major upper gastrointestinal, liver and
pancreatic surgery, irrespective of language, blinding or publication status for inclusion in the review.
Data collection and analysis
Two review authors independently identified trials and independently extracted data. We calculated the risk ratio (RR), mean difference
(MD), or standardised mean difference (SMD) with 95% confidence intervals (CIs) using both fixed-effect and random-effects models
using Review Manager 5, based on available case analysis.
1Enhanced recovery protocols for major upper gastrointestinal, liver and pancreatic surgery (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Main results
Ten studies met the inclusion criteria for the review, and nine studies provided information on one or more outcomes for the review.
A total of 1014 participants were randomly assigned to the enhanced recovery protocol (499 participants) or standard care (515
participants) in the nine RCTs. Most of the trials included low anaesthetic risk participants with high performance status undergoing
different upper gastrointestinal, liver and pancreatic surgeries. Eight trials incorporated more than one element of the enhanced recovery
protocol. All of the trials were at high risk of bias. The overall quality of evidence was low or very low.
None of the trials reported long-term mortality, medium-term health-related quality of life(three months to one year), time to return to
normal activity, or time to return to work. The difference between the enhanced recovery protocol and standard care were imprecise for
short-term mortality (enhanced recovery protocol: 4/425 (adjusted proportion = 0.6%); standard care: 1/443 (0.2%); seven trials; 868
participants; RR 2.79; 95% CI 0.44 to 17.73; very low quality evidence), proportion of people with serious adverse events (enhanced
recovery protocol: 4/157 (adjusted proportion = 0.6%); standard care: 0/184 (0.0%); two trials; 341 participants; RR 5.57; 95%CI 0.68
to 45.89; very low quality evidence), number of serious adverse events (enhanced recovery protocol: 34/421 (8 per 100 participants);
standard care: 46/438 (11 per 100 participants); seven trials; 859 participants; rate ratio 0.72; 95% CI 0.45 to 1.13; very low quality
evidence), health-related quality of life (four trials; 373 participants; SMD 0.29; 95% CI -0.04 to 0.62; very low quality evidence)
and hospital readmissions (enhanced recovery protocol: 14/355 (adjusted proportion = 3.3%); standard care: 9/378 (2.4%); seven
trials; 733 participants; RR 1.4; 95% CI 0.69 to 2.87; very low quality evidence). The enhanced recovery protocol group had a lower
proportion of people with mild adverse events (enhanced recovery protocol: 31/254 (adjusted proportion = 10.9%); standard care: 51/
271 (18.8%); four trials; 525 participants; RR 0.58; 95% CI 0.39 to 0.85; low quality evidence), fewer number of mild adverse events
(enhanced recovery protocol: 69/499 (13 per 100 participants); standard care: 128/515 (25 per 100 participants); nine trials; 1014
participants; rate ratio 0.52; 95% CI 0.39 to 0.70; low quality evidence), shorter length of hospital stay (nine trials; 1014 participants;
MD -2.19 days; 95% CI -2.53 to -1.85; low quality evidence) and lower costs (four trials; 282 participants; MD USD -6300; 95% CI
-8400 to -4200; low quality evidence) than standard care group.
Authors’ conclusions
Based on low quality evidence, enhanced recovery protocols may reduce length of hospital stay and costs (primarily because of reduction
in hospital stay) in people undergoing major upper gastrointestinal, liver and pancreatic surgeries. However, the validity of the results
is uncertain because of the risk of bias in the trials and the way the outcomes were measured. Future RCTs should be conducted with
low risk of bias, and measure clinically important outcomes for including the three months to one year period.
P L A I N L A N G U A G E S U M M A R Y
Enhanced recovery protocols in people undergoing major surgeries of food pipe (oesophagus), stomach, liver and pancreas
Review question
Are enhanced recovery protocols beneficial or harmful when compared to standard surgery in people undergoing major surgeries of
food pipe (oesophagus), stomach, liver and pancreas?
Background
’Fast-track surgery’ or ’enhanced recovery protocol’ or ’fast-track rehabilitation’ incorporates one or more of the following components:
patient education before surgery, pain relief during and after surgery, early mobilisation after surgery, nutritional supplements, and
feeding through the mouth or through a tube introduced into the gut through the nose or through the tummy wall rather than by
drip to quicken the recovery after surgery. The benefits and harms of using an enhanced recovery protocol in people undergoing major
surgeries of oesophagus, stomach, liver and pancreas are not known. We sought to resolve this issue by searching for existing studies on
the topic. We included all studies whose results were reported until 26 March 2015.
Study characteristics
Ten studies met the inclusion criteria for the review, and nine studies provided information for the review. A total of 1014 participants
received an enhanced recovery protocol (499 participants) or standard care (515 participants) in the nine trials. The decision on whether
a participant received an enhanced recovery protocol or standard care was made using methods similar to the toss of a coin, ensuring that
the participants in the two groups were similar. One additional trial (including 33 participants) also performed the same comparison
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but did not provide any information for this review. Most of the trials included persons who were healthy in aspects other than the
condition requiring surgery. Eight trials incorporated more than one component of the enhanced recovery protocol.
Key results
None of the trials reported long-term deaths, medium-term health-related quality of life (three months to one year), time to return
to normal activity, or time to return to work. The difference between enhanced recovery protocols and standard care was imprecise
for short-term deaths, percentage of people with major complications, total number of major complications, health-related quality of
life and hospital readmissions. Enhanced recovery protocols had a lower percentage of people with minor complications, fewer minor
complications, shorter length of hospital stay (approximately two days shorter hospital stay per person) and lower costs (cost savings of
approximately USD 6300 per person) compared to standard care. Because the trials were of poor quality and did not include clinically
important end points, future high quality studies are needed in this field.
Quality of the evidence
The quality of evidence was low or very low. As a result, there is a lot of uncertainty regarding the results.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Enhanced recovery protocols versus standard care for major upper gastrointestinal, liver and pancreatic surgery
Patient or population: people with major upper gastrointestinal, liver and pancreatic surgery
Settings: secondary or tertiary care
Intervention: enhanced recovery protocol
Control: standard care
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Enhanced recovery pro-
tocol versus standard
care
None of the trials reported long-term mortality, medium-term health-related quality of life (3 months to 1 year), time to return to normal activity, or time to return to work.
Short-term mortality 2 per 1000 6 per 1000
(1 to 40)
RR 2.79
(0.44 to 17.73)
868
(7 studies)
⊕©©©
very low1,2,3
Serious adverse events
(proportion)
1 per 1000 6 per 1000
(1 to 46)
RR 5.57
(0.68 to 45.89)
341
(2 studies)
⊕©©©
very low1,2,3
Since there were no se-
rious adverse events in
the control group (in the
two trials that reported
the proportion of partic-
ipants with serious ad-
verse events), the con-
trol group risk was stated
as 0.1% for this outcome
alone
Serious adverse events
(number)
105 per 1000 76 per 1000
(47 to 119)
Rate ratio 0.72
(0.45 to 1.13)
859
(7 studies)
⊕©©©
very low1,2,3
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Health-related quality of
life (until 3 months)
The mean health-related
quality of life in the inter-
vention groups was
0.29 standard deviations
higher
(0.04 lower to 0.62
higher)
373
(4 studies)
very low1,4 SMD 0.29 (-0.04 to 0.62)
Mild adverse events
(proportion)
188 per 1000 109 per 1000
(73 to 160)
RR 0.58
(0.39 to 0.85)
525
(4 studies)
⊕⊕©©
low1
Mild adverse events
(number)
249 per 1000 129 per 1000
(97 to 174)
Rate ratio 0.52
(0.39 to 0.70)
1014
(9 studies)
⊕⊕©©
low1
Length of hospital stay The mean length of hos-
pital stay in the control
groups was
8 days
The mean length of hos-
pital stay in the interven-
tion groups was
2.19 lower
(2.53 to 1.85 lower)
1014
(9 studies)
⊕⊕©©
low1
The length of hospital stay
reported in the trials in-
cluded only the length
of hospital stay during
the admission for surgery
and does not include the
readmissions
Readmissions 24 per 1000 33 per 1000
(16 to 68)
RR 1.4
(0.69 to 2.87)
733
(7 studies)
⊕©©©
very low1,2,3
Costs The mean costs in the
control groups were
USD 7000
The mean costs in the in-
tervention groups were
0.63 lower
(0.84 to 0.42 lower)
282
(4 studies)
⊕⊕©©
low1
*The basis for the assumed risk is the mean control group risk. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the
relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 The risk of bias was high in all the trials.
2 The confidence intervals were wide (overlaps 0 and 0.75 or 1.25).
3 The total sample size was less than the sample required in a single trial.
4 The confidence intervals were wide (overlaps 0 and 0.25 or -0.25).
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Description of the condition
Upper gastrointestinal disorders include diseases affecting the oe-
sophagus, stomach, liver, gallbladder and pancreas. The definition
ofmajor upper gastrointestinal, liver and pancreatic surgery is vari-
able. One definition that we have used in this review includes all
upper gastrointestinal, liver and pancreatic surgeries that have been
excluded from the British Association of Day Surgery Directory of
Procedures (BADS 2012), as well as surgeries such as transhiatal
oesophagectomy, gastrectomy (irrespective of whether a total or
subtotal distal gastrectomy is performed), liver resection (irrespec-
tive of the number of segments resected and the aetiology), pan-
creatic resection (irrespective of whether a pancreaticoduodenec-
tomy or a distal pancreatectomy is performed, and irrespective
of whether the pylorus is preserved), pancreatic drainage proce-
dures (for chronic pancreatitis) and open pancreaticojejunostomy
or pancreaticogastrostomy for pseudocyst. In upper gastrointesti-
nal surgeries that are included in the British Association of Day
Surgery Directory of Procedures (BADS 2012), early mobilisation
and discharge are recommended when possible, and patients are
admitted because of coexistingmedical illnesses, for administrative
reasons, because of complications related to surgery, or because of
intolerance to surgery. As will be evident from the description of
the intervention, earlymobilisation is one of the elements of an en-
hanced recovery protocol; therefore this review includes only up-
per gastrointestinal, liver and pancreatic surgeries that are not in-
cluded in the British Association of Day Surgery Directory of Pro-
cedures (BADS 2012). The number of major upper gastrointesti-
nal, liver and pancreatic surgeries performed each year is difficult
to estimate. In the UK alone, approximately 25,000 major upper
gastrointestinal, liver and pancreatic surgeries are performed, cost-
ing approximately GBP 150 million each year (Hospital Episode
Statistics 2013).
Description of the intervention
’Fast-track surgery’ or ’enhanced recovery protocol’ or ’fast-track
rehabilitation’ after surgery, again can be variably defined, and
involves one or more of the following elements (Kehlet 1997).
1. Preoperative information and teaching.
2. Decreased stress related to surgery.
3. Pain relief.
4. Exercise (early mobilisation).
5. Enteral nutrition.
6. Growth factors.
How the intervention might work
Enhanced recovery protocols aim to decrease pathophysiological
changes after surgery, including surgical stress, pain, immunosup-
pression, nausea, vomiting and ileus, hypoxaemia, immobilisa-
tion leading to blood clots in the legs and malnutrition leading to
catabolism and muscle wasting (Kehlet 1997).
Why it is important to do this review
Implementation of enhanced recovery protocols involves consid-
erable planning (including identifying the elements that need to
be incorporated into the protocol for a particular surgery) and
deployment (which involves educating and training the staff and
encouraging staff members, including surgeons, to follow a uni-
fied protocol). Deployment may involve changing traditions and
beliefs of surgeons and other clinicians who may be reluctant to
change their traditional practices, or who may be concerned that
the enhanced recovery protocol may be associated with patient
risks and harms. It also incurs costs. Thus, implementation of en-
hanced recovery protocols involves considerable human and re-
source management. It is therefore essential to assess whether an
enhanced recovery protocol is effective for major upper gastroin-
testinal, liver and pancreatic surgery. No Cochrane review on this
topic has been conducted.
O B J E C T I V E S
To assess the benefits and harms of enhanced recovery protocols
compared with standard care (or usual practice) in major upper
gastrointestinal, liver and pancreatic surgery.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) reported as full-
text, those published as abstract only, and those with unpublished
data.
Types of participants
We included adults, or children, or both, undergoing major upper
gastrointestinal, liver and pancreatic surgery such as transhiatal
oesophagectomy, gastrectomy (irrespective of whether a total or
subtotal distal gastrectomy is performed), liver resection (irrespec-
tive of the number of segments resected and the aetiology), pan-
creatic resection (irrespective of whether a pancreaticoduodenec-
tomy or a distal pancreatectomy is performed, and irrespective
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of whether the pylorus is preserved), pancreatic drainage proce-
dures (for chronic pancreatitis) and open pancreaticojejunostomy
or pancreaticogastrostomy for pseudocyst.
We excluded upper gastrointestinal, liver and pancreatic surgeries
that are included in the British Association of Day Surgery Direc-
tory of Procedures (BADS 2012), including laparoscopic cholecys-
tectomy or laparoscopic fundoplication, as patients are discharged
on the same day when they have mobilised adequately.
Types of interventions
We included trials comparing an enhanced recovery protocol with
usual care, provided that the only difference between randomly
assigned groups is the use of an enhanced recovery protocol. We
will accept the definition proposed by Kehlet 1997, which requires
inclusion of one or more of the following elements.
1. Preoperative information and teaching.
2. Decreased stress related to surgery.
3. Pain relief.
4. Exercise (early mobilisation).
5. Enteral nutrition.
6. Growth factors.
We excluded trials comparing different enhanced recovery pro-
tocols. We also excluded trials comparing laparoscopic and open
surgeries, as the issues surrounding laparoscopic or open surgery
are different for different procedures.
Types of outcome measures
Primary outcomes
1. Mortality.
i) Short-term mortality (in-hospital mortality or
mortality within three months).
ii) Long-term mortality (for patients undergoing surgery
for cancer).
2. Serious adverse events (within three months). We accepted
the following definitions of serious adverse events.
i) Clavien-Dindo classification (Clavien 2009; Dindo
2004): grade III or higher.
ii) International Conference on Harmonisation-Good
Clinical Practice (ICH-GCP) guideline (ICH-GCP 1996):
serious adverse events defined as any untoward medical
occurrences that result in death, are life threatening, require
inpatient hospitalisation or prolongation of existing
hospitalisation and result in persistent or significant disability/
incapacity.
iii) Individual complications that could clearly be
classified as grade III or higher by the Clavien-Dindo
classification (Clavien 2009; Dindo 2004), or as a serious adverse
event by the ICH-GCP classification.
3. Health-related quality of life (using any validated scale).
i) Short-term (until three months).
ii) Medium-term (three months to one year).
Secondary outcomes
1. Adverse events (within three months). We included all
adverse events reported by the study authors, irrespective of their
severity.
2. Length of hospital stay (including the index admission for
major upper gastrointestinal, liver or pancreatic surgery and any
surgical complication-related readmissions).
3. Number of hospital readmissions.
4. Time to return to normal activity (return to preoperative
mobility without additional carer support).
5. Time to return to work (for those who were employed
previously).
6. Costs (however reported by study authors; we converted
costs to the single currency of USD based on the existing
conversion rate on the day of the analysis).
The selection of the above clinical outcomes was based on the ne-
cessity to assess whether an enhanced recovery protocol decreases
complications after surgery and results in earlier postoperative re-
covery, allowing earlier discharge from hospital, return to normal
activity, return to work and improvement in health-related quality
of life.
Reporting of the outcomes listed here will not be an inclusion
criterion for the review.
Search methods for identification of studies
Electronic searches
We conducted a literature search to identify all published and un-
published RCTs until 26th March 2015. This literature search
identified potential studies published in all languages. We trans-
lated the non-English language papers and fully assessed them for
potential inclusion in the review as necessary.
We searched the following electronic databases to identify poten-
tial studies.
1. Cochrane Central Register of Controlled Trials
(CENTRAL; Cochrane Library; 2015, Issue 3) (Appendix 1).
2. MEDLINE (OvidSP) (1966 to March 2015) (Appendix 2).
3. EMBASE (OvidSP) (1988 to March 2015) (Appendix 3).
4. Science Citation Index (Web of Knowledge) (1982 to
March 2015) (Appendix 4).
We also conducted a search of ClinicalTrials.gov (Appendix 5)
and the World Health Organization International Clinical Trials
Registry Platform (WHO ICTRP) (Appendix 6) on 26th March
2015.
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Searching other resources
We checked reference lists of all primary studies and review arti-
cles for additional references. We contacted authors of identified
trials and asked them to identify other published and unpublished
studies.
We searched for errata or retractions from eligible trials on http:/
/www.ncbi.nlm.nih.gov/pubmed on 26th March 2015, but did
not find any errata.
Data collection and analysis
Selection of studies
Two review authors (GBS and AB) independently screened titles
and abstracts for inclusion of all potential studies identified as a
result of the search and coded them as ’retrieve’ (eligible or poten-
tially eligible/unclear) or ’do not retrieve.’
We retrieved full-text study reports, and the two review authors
(GBS and AB) independently screened them, identified studies
for inclusion and identified and record reasons for exclusion of
ineligible studies.
We resolved disagreements through discussion and, when re-
quired, consulted a third person (KG).We identified and excluded
duplicates and collated multiple reports of the same study, so that
each study rather than each report is the unit of interest in the
review. We recorded the selection process in sufficient detail to
complete a PRISMA (Preferred Reporting Items for Systematic
Reviews and Meta-Analyses) flow diagram (Moher 2009; Figure
1), and a Characteristics of excluded studies table.
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Figure 1. Study flow diagram.
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Data extraction and management
We used a standard data collection form for study characteristics
and outcome data that was piloted on two studies in the review.
The two review authors (GBS and AB) extracted the following
study characteristics from included studies.
1. Methods: study design, total duration of study and run-in,
number of study centres and locations, study settings,
withdrawals, dates of study.
2. Participants: number (N), mean age, age range, gender,
inclusion criteria, exclusion criteria.
3. Interventions: interventions, comparisons, concomitant
interventions.
4. Outcomes: primary and secondary outcomes specified and
collected, time points reported.
5. Notes: funding for trial, notable conflicts of interest of trial
authors.
Two review authors (GBS and AB) independently extracted out-
come data from the included studies. If outcomes were reported
multiple times for the same time point, for example, if short-
term health-related quality of life was reported at six weeks and
at three months, we planned to choose the later time point (i.e.
three months) for data extraction. For time-to-event outcomes, we
planned to extract data to calculate the natural logarithm of the
hazard ratio and its standard error using the methods suggested by
Parmar 1998.
We planned to include all randomly assigned participants for the
medium- and long-term outcomes (e.g. mortality, quality of life),
and this was not conditional upon short-term outcomes (e.g. being
alive at three months, having a low or high quality of life index at
three months).
We noted in the Characteristics of included studies table whether
outcome data were reported in an unusable way. We resolved dis-
agreements by reaching consensus or by involving a third person
(KG). One review author (KG) copied data from the data collec-
tion form into the Review Manager file (RevMan 2014). We dou-
ble-checked that data were entered correctly by comparing data in
the study reports with data presented in the systematic review.
Assessment of risk of bias in included studies
Two review authors (GBS and AB) independently assessed risk
of bias for each study, using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
Disagreements were resolved by discussion or through involve-
ment of a third assessor (KG). We assessed risk of bias according
to the following domains.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.
We graded each potential source of bias as high, low or unclear
risk and provided a quote from the study report together with a
justification for our judgement in the ’Risk of bias’ table. We sum-
marised risk of bias judgements across different studies for each of
the domains listed. We considered blinding separately for differ-
ent key outcomes when necessary (e.g. for unblinded outcome as-
sessment, risk of bias for all-cause mortality may be very different
than for a patient-reported pain scale). When information on risk
of bias was related to unpublished data or correspondence with a
trialist, we noted this in the ’Risk of bias’ table.
When considering treatment effects, we took into account the risk
of bias for studies that contribute to those outcomes.
Assesment of bias in conducting the systematic
review
We conducted the review according to the published protocol and
reported deviations from the protocol in the Differences between
protocol and review’ section of this review.
Measures of treatment effect
We analysed dichotomous data as risk ratios (RRs) and continuous
data as mean differences (MDs) when the outcome was reported
or converted to the same units in all trials (e.g. hospital stay) or as
standardised mean differences (SMDs) when different scales were
used in measuring the outcome (e.g. quality of life). We ensured
that higher scores for continuous outcomes had the samemeaning
for the particular outcome, explained the direction to the reader
and reported when the directions were reversed.
We calculated rate ratios for outcomes such as adverse events and
serious adverse events when it was possible for the same person to
experience more than one adverse event (or serious adverse event).
If the study authors had calculated the rate ratio of adverse events
(or serious adverse events) for intervention versus control on the
basis of Poisson regression, we planned to obtain the rate ratio
by using the Poisson regression method in preference to the rate
ratio calculated using the number of adverse events (or serious
adverse events) reported during a specified period. We planned to
calculate the hazard ratio for time-to-event outcomes such as long-
term mortality and long-term recurrence.
We undertook meta-analyses since all the surgeries were major
hepato pancreato biliary surgeries. Trialists commonly indicate
when they have skewed data by reporting medians and interquar-
tile ranges. It was not possible to determine whether the data were
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skewed. We attempted to contact the trial authors to provide this
information, but we were unable to obtain this information. So, if
the median and interquartile range were reported, we imputed the
mean and standard deviation (as mentioned in the Dealing with
missing data), but we performed a sensitivity analysis, excluding
the data from these trials (as mentioned in the Sensitivity analysis).
Whenmultiple trial armswere reported in a single trial, we planned
to include only the relevant arms. When two comparisons (e.g.
enhanced recovery protocol A versus standard care and enhanced
recovery protocol B versus standard care) had to be entered into the
samemeta-analysis, we planned to pool the results of enhanced re-
covery protocol A and enhanced recovery protocol B and compare
them with standard care. The alternative way of including such
trials is to half the control group and compare it with enhanced
recovery protocol A and with enhanced recovery protocol B to
avoid double counting. We planned to perform a sensitivity anal-
ysis to determine whether results obtained using the two methods
of dealing with multi-arm trials led to different conclusions.
Unit of analysis issues
The unit of analysis was individual study participants undergoing
major upper gastrointestinal, liver and pancreatic surgery. If clus-
ter-randomised trials were identified, we planned to obtain the ef-
fect estimate adjusted for the clustering effect. If this was not avail-
able, we planned to perform a sensitivity analysis by excluding the
trial from the meta-analysis, as the variance of the effect estimate
unadjusted for cluster effect is less than the actual variance, which
is adjusted for cluster effect, inappropriately giving more weight
to the cluster-RCT in the meta-analysis.
Dealing with missing data
We attempted to contact the investigators or study sponsors to
verify key study characteristics and to obtain missing numerical
outcome data whenever possible (e.g. when a study is identified
as an abstract only). We received additional data from two study
authors (Jones 2013; Kim 2012). If we were unable to obtain in-
formation from investigators or study sponsors, we imputed mean
from median (i.e. consider median as the mean) and standard de-
viation from standard error, interquartile range or P values accord-
ing to the recommendations of the Cochrane Handbook for Sys-
tematic Reviews of Interventions (Higgins 2011), but we assessed
the impact of including such studies as indicated in a sensitivity
analysis.
If wewere unable to calculate the standard deviation from the stan-
dard error, interquartile range or P values, we imputed the stan-
dard deviation as the highest standard deviation in the remaining
trials included in the outcome, while remaining fully aware that
this method of imputation will decrease the weight of the studies
in the meta-analysis of MDs and will shift the effect towards no
effect for SMDs.
Assessment of heterogeneity
We used the I² statistic to measure heterogeneity among the trials
in each analysis. If we identified substantial heterogeneity as per the
Cochrane Handbook for Systematic Reviews of Interventions (greater
than 50% to 60%), we planned to explore this by performing
prespecified subgroup analysis (Higgins 2011).
Assessment of reporting biases
We attempted to contact study authors to ask them to provide
missing outcomedata.When thiswas not possible, and themissing
datawere thought to introduce serious bias, we explored the impact
of including such studies in the overall assessment of results by a
sensitivity analysis.
Since there were fewer than 10 trials for all the outcomes, we did
not create and examine a funnel plot to explore possible publica-
tion biases. We planned to use Egger’s test to determine the statis-
tical significance of the reporting bias (Egger 1997). We planned
to use a P value less than 0.05 to show statistically significant re-
porting bias.
Data synthesis
We performed analyses using Review Manager 5.3 (RevMan
2014). We used the Mantel Haenszel method for dichotomous
data, inverse variance method for continuous data and generic
inverse variance for count data. We planned to use generic in-
verse variance for time-to-event data. We used both the fixed-ef-
fect model (DerSimonian 1986), and random-effects model for
the analysis (Demets 1987). In case of discrepancy between the
two models, we reported both results; otherwise we reported only
the results from the fixed-effect model.
’Summary of findings’ table
We created a ’Summary of findings’ table using all outcomes. We
used the five GRADE (Grades of Recommendation, Assessment,
Development and Evaluation) considerations (study limitations,
consistency of effect, imprecision, indirectness and publication
bias) to assess the quality of a body of evidence as it related to the
studies that contributed data to the meta-analyses for prespecified
outcomes.
We used methods and recommendations as described in Section
8.5 and Chapter 12 of the Cochrane Handbook for Systematic Re-
views of Interventions (Higgins 2011), and used GRADEpro soft-
ware (GRADEproGDT 2015).We justified all decisions to down-
grade or upgrade the quality of studies by using footnotes and
making comments to aid the reader’s understanding of the review
whenever necessary. We planned to consider whether any addi-
tional outcome information could not be incorporated into the
meta-analyses and noted this in the comments, stating whether it
supported or contradicted the information derived from themeta-
analyses.
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Subgroup analysis and investigation of heterogeneity
We planned to carry out the following subgroup analyses.
1. Different surgeries (e.g. total or subtotal gastrectomy, distal
gastrectomy, pancreaticoduodenectomy, distal pancreatectomy).
2. Different enhanced recovery protocols (according to the
element that the enhanced recovery protocol is meant to address,
for example, pain relief, nutrition).
3. Adults versus children.
We planned to use the primary outcomes in the subgroup analysis.
We used the formal Chi2 test for subgroup differences to test for
subgroup interactions.
Sensitivity analysis
We performed sensitivity analysis, as defined a priori, to assess the
robustness of our conclusions. This involved:
1. excluding trials at unclear or high risk of bias (one of more
of the risk of bias domains is classified as unclear or high);
2. excluding trials for which mean or standard deviation or
both were imputed; and
3. excluding cluster-RCTs for which adjusted effect estimates
are not reported.
4. different methods of dealing with multi-arm trials (please
see Measures of treatment effect).
Reaching conclusions
We based our conclusions only on findings from the quantitative
or narrative synthesis of studies included in this review. We have
avoided making recommendations for practice, and our implica-
tions for research will give the reader a clear sense of what the
focus of future research in the area should be; we have identified
remaining uncertainties.
R E S U L T S
Description of studies
Results of the search
We identified 4046 references through electronic searches of the
Cochrane Central Register of Controlled Trials (CENTRAL) (n
= 324), MEDLINE (OvidSP) (n = 1087), EMBASE (OvidSP)
(n = 731), Science Citation Index expanded (n = 1737), Clini-
calTrials.gov (n = 89) and the WHO Trials register (n = 78). Af-
ter removing duplicate references there were 2731 references. We
excluded 2701 clearly irrelevant references through reading ab-
stracts. We retrieved a total of 30 references for further assessment
in detail, from the full publication. We excluded 11 references for
the reasons listed in the Characteristics of excluded studies tables.
Four references were references of ongoing trials (Characteristics
of ongoing studies). Four references are awaiting classification Of
these, two were published as abstracts and it is not clear whether
an intervention that can be classified as an enhanced recovery pro-
tocol was included as one of the arms (Geubbels 2014; Jin 2013).
One reference has been published as full-text but we were unable
to obtain the full-text in order to assess eligibility (Wang 2014).
One reference was identified as completed in the ClinicalTrials.gov
trial register, but we could not identify any publication as abstract
or full-text. We were unable to obtain the results for any of these
trials. Eleven references of 10 RCTs fulfilled the inclusion criteria
(Characteristics of included studies). The reference flow is shown
in Figure 1.
Included studies
We included a total of 10 RCTs (Barlow 2011; Jones 2013; Kim
2012; Lemanu 2013; Liu 2010; Lu 2014;Miyachi 2013; Ni 2013;
Wang 2010; Zhao 2014). All of the 10 RCTs were two-armed
trials. A total of 1115 participants were randomised to either an
enhanced recovery protocol or standard recovery protocol group.
A total of 68 were excluded after randomisation for various rea-
sons stated in the Characteristics of included studies. The mean
or median age in the trials ranged from 44 years to 66 years. The
average proportion of females ranged from 17.8% to 70.5%. The
type of surgeries that the participants underwent is summarised in
Table 1.Three trials includedparticipants undergoing gastrectomy
(Liu 2010; Miyachi 2013; Wang 2010) and three trials included
participants undergoing liver surgery (Jones 2013; Lu 2014; Ni
2013). The participants underwent major upper gastrointestinal
surgery, laparoscopic distal gastrectomy, laparoscopic sleeve gas-
trectomy, oesophagectomy in each of the remaining trials (Barlow
2011; Kim 2012; Lemanu 2013; Zhao 2014). The detailed inclu-
sion and exclusion criteria of participants in the different trials are
stated in the Characteristics of included studies tables.
The elements of the enhanced recovery protocol that were differ-
ent between the intervention and control in the different studies
are summarised in Table 1 and Characteristics of included studies
tables. Seven trials incorporated preoperative patient education in
addition to the standard care (Jones 2013; Kim 2012; Lemanu
2013; Liu 2010; Ni 2013; Wang 2010; Zhao 2014). Six trials in-
corporated a pain relief regimen which was different between the
enhanced recovery protocol and standard care (Kim 2012; Lemanu
2013; Liu 2010; Ni 2013; Wang 2010; Zhao 2014). Seven trials
incorporated early mobilisation in the enhanced recovery proto-
col care group in addition to the standard care (Jones 2013; Kim
2012; Lemanu 2013; Liu 2010; Lu 2014; Ni 2013; Wang 2010).
Eight trials incorporated early enteral nutrition in one form or
the other in addition to the standard care (Barlow 2011; Jones
2013; Kim 2012; Lemanu 2013; Liu 2010; Lu 2014; Ni 2013;
Wang 2010). One trial incorporated growth factors in the en-
13Enhanced recovery protocols for major upper gastrointestinal, liver and pancreatic surgery (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
hanced recovery protocol care group in addition to the standard
care (Miyachi 2013). Eight trials incorporated more than one ele-
ment of the enhanced recovery protocol in the enhanced recovery
protocol group compared to the standard care group (Jones 2013;
Kim 2012; Lemanu 2013; Liu 2010; Lu 2014; Ni 2013; Wang
2010; Zhao 2014). The outcomes reported in the trials are sum-
marised in Table 1. Nine trials including a total of 1014 partici-
pants randomised to the enhanced recovery protocol (499 partic-
ipants) and standard care (515 participants) provided data on one
or more outcomes and could be included in the meta-analysis.
Excluded studies
We excluded three trials as they were comparisons between two
enhanced recovery protocols (Gillissen 2011; Hendry 2010; Revie
2012). We excluded four trials as they included patients undergo-
ing surgeries, but were not specific to major upper gastrointesti-
nal, liver or pancreatic surgeries (Cheifetz 2010; Hubner 2012;
Serclova 2009; Wattchow 2009). We excluded three studies as
they were non-randomised studies (Dejong 2014; Feldman 2014;
Sahoo 2014). We excluded another reference as it was a comment
on an included trial (Strobel 2013).
Risk of bias in included studies
None of the trials were considered to be at low risk of bias. All
the trials had unclear or high risk of bias on one or more domains
(Figure 2; Figure 3). All-causemortality is unlikely to be influenced
by the lack of blinding, while all the remaining outcomes are likely
to be biased towards the enhanced recovery protocol because of
lack of blinding. Blinding of participants is impossible for some
of the elements of the enhanced recovery protocol (preoperative
education and early mobilisation). Eight trials included at least
one of preoperative education and early mobilisation (Jones 2013;
Kim 2012; Lemanu 2013; Liu 2010; Lu 2014; Ni 2013; Wang
2010; Zhao 2014). It would have been impossible to blind the
participants and the healthcare provider in these trials. So, we
assessed whether the above trials were at low risk of other biases;
none of the trials were at low risk of bias even after excluding the
blinding of participants and personnel domain.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Five trials described random sequence generation and allocation
concealment adequately (Barlow 2011; Jones 2013; Kim 2012;
Lemanu 2013; Zhao 2014). We considered these five trials to be
at low risk of selection bias; the selection bias in the remaining
trials was unclear.
Blinding
No trials reported that the participants and healthcare personnel
involved in patient care or the outcome assessors were blinded
and so we considered all trials to be at unclear or high risk of
performance and detection bias.
Incomplete outcome data
Two trials had no post-randomisation drop-outs and we consid-
ered them to be at low risk of attrition bias (Barlow 2011; Ni
2013). The remaining trials had post-randomisation drop-outs,
particularly; they excluded participants who developed complica-
tions during surgery, or participants who did not follow the pro-
tocol to which they were randomised.
Selective reporting
Four trials reported mortality and morbidity adequately and we
considered them to be at low risk of selective reporting bias (
Barlow 2011; Jones 2013; Kim 2012; Ni 2013). The remaining
trials did not report the mortality and morbidity or did not report
the severity of the morbidity; we were unable to locate the trial
protocol for these trials to compare whether the outcomes reported
in the final report were in the same order as in the protocol. We
considered these trials to be at high risk of selective reporting.
Other potential sources of bias
Six trials reported the source of funding (Barlow 2011; Jones 2013;
Kim 2012; Lemanu 2013; Ni 2013; Zhao 2014), out of which
we considered five trials to be at low risk of bias due to source of
funding (Barlow 2011; Jones 2013; Lemanu 2013; Ni 2013; Zhao
2014); the risk of bias due to source of funding was unclear in the
remaining trials. We did not identify any other risks of bias in the
trials which could have influenced the effect estimates.
Effects of interventions
See: Summary of findings for the main comparison Enhanced
recovery protocol versus standard care for major upper
gastrointestinal, liver and pancreatic surgery
None of the trials reported long-term mortality, medium-term
health-related quality of life, time to return to normal activity,
or time to return to work. A summary of the effect estimates
is available in Summary of findings for the main comparison.
The quality of evidence was low (mild adverse events: proportion
and number of events, length of hospital stay, and costs) or very
low (short-term mortality, serious adverse events: proportion and
number, health-related quality of life, and readmissions) for the
outcomes reported in the trials.
Primary outcomes
Short-term mortality
Seven trials (868 participants) reported short-term mortality
(Barlow 2011; Jones 2013; Kim 2012; Liu 2010; Lu 2014; Ni
2013; Wang 2010). There was no statistically significant differ-
ence in the short-term mortality between the enhanced recovery
protocol and standard care (risk ratio (RR) 2.79, 95% confidence
interval (CI) 0.44 to 17.73; Analysis 1.1). There was no change
in the statistical significance by using the random-effects model.
There was no evidence of heterogeneity (I2 = 0%; P = 0.36).
Serious adverse events
Two trials (341 participants) reported the proportion of partici-
pants with serious adverse events (Kim 2012; Liu 2010). There
was no statistically significant difference in the proportion of par-
ticipants with serious adverse events between the enhanced recov-
ery protocol and standard care (RR 5.57, 95% CI 0.68 to 45.89;
Analysis 1.2). There was no change in the statistical significance
by using the random-effects model. There was no evidence of het-
erogeneity (I2 = 0%; P = 0.64).
Seven trials (859 participants) reported the number of serious ad-
verse events (Barlow 2011; Jones 2013; Kim 2012; Lemanu 2013;
Lu 2014; Ni 2013; Zhao 2014). There was no statistically signifi-
cant difference in the number of participants with serious adverse
events between the enhanced recovery protocol and standard care
(rate ratio 0.72, 95% CI 0.45 to 1.13; Analysis 1.3). There was no
change in the statistical significance by using the random-effects
model. There was no evidence of heterogeneity (I2 = 16%; P =
0.31).
Health-related quality of life (until three months)
Four trials (373 participants) reported health-related quality of life
(Jones 2013; Kim 2012; Lemanu 2013; Ni 2013). One trial mea-
sured health-related quality of life at five days after surgery using
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the General Comfort Questionnaire (GCQ measured by Kolcaba
Line; Ni 2013). Two trials measured health-related quality of life
at 14 days after surgery using the Surgical Recovery Scale (which
measures postoperative fatigue) (Lemanu 2013), and theEuropean
Organisation for Research and Treatment of Cancer (EORTC)
QLQ C-30 (Kim 2012). One trial measured the health-related
quality of life at various time points until 28 days after surgery
using the EQ-5D questionnaire and reported the area under the
curve of the health-related quality of life (Jones 2013). The health-
related quality of life was statistically significantly better with en-
hanced recovery protocols than standard care using the fixed-effect
model (standardised mean difference (SMD) 0.33, 95% CI 0.13
to 0.54). However, on using the random-effects model, there was
no statistically significant difference in the health-related quality
of life between the enhanced recovery protocol and standard care
(SMD 0.29, 95% CI -0.04 to 0.62) (Analysis 1.4). There was
moderate heterogeneity (I2 = 57%; P = 0.07). The mean and stan-
dard deviation were imputed from the median and P value from
one of the trials (Jones 2013). Exclusion of this trial did not alter
the statistical significance of the results (SMD 0.17, 95% CI -0.19
to 0.53; Analysis 3.1).
Secondary outcomes
Mild adverse events
Four trials (525 participants) reported the proportion of partic-
ipants with mild adverse events (Barlow 2011; Kim 2012; Liu
2010; Lu 2014). The proportion of participants with mild adverse
events was statistically significantly better with enhanced recov-
ery protocols than standard care (RR 0.58, 95% CI 0.39 to 0.85)
(Analysis 1.5). There was no change in the statistical significance
by using the random-effects model. There was no evidence of het-
erogeneity (I2 = 0%; P = 0.87).
Nine trials (1014 participants) reported the number of mild ad-
verse events (Barlow 2011; Jones 2013; Kim 2012; Lemanu 2013;
Liu 2010; Lu 2014; Ni 2013;Wang 2010; Zhao 2014). The num-
ber of mild adverse events was statistically significantly better with
enhanced recovery protocols than standard care (rate ratio 0.52,
95% CI 0.39 to 0.70; Analysis 1.6). There was no change in the
statistical significance by using the random-effects model. There
was no evidence of heterogeneity (I2 = 0%; P = 0.47).
Length of hospital stay
Nine trials (1014 participants) reported length of hospital stay
(Barlow 2011; Jones 2013; Kim 2012; Lemanu 2013; Liu 2010;
Lu 2014; Ni 2013; Wang 2010; Zhao 2014). The length of hos-
pital stay reported in the trials included only the length of hospital
stay during the admission for surgery and does not include the
readmissions. The length of hospital stay was statistically signif-
icantly shorter with enhanced recovery protocols than standard
care (MD -2.19 days, 95% CI -2.53 to -1.85; Analysis 1.7). There
was no change in the statistical significance by using the random-
effects model. There was moderate heterogeneity (I2 = 66%; P =
0.003). The mean and standard deviation were imputed from the
median and interquartile range or P value from six trials (Barlow
2011; Jones 2013; Lemanu 2013; Lu 2014; Wang 2010; Zhao
2014). The difference in the median hospital stay between en-
hanced recovery protocols and standard care ranged from one day
and five days favouring enhanced recovery protocols (shorter hos-
pital stay in enhanced recovery protocols). Excluding the trials in
which mean and standard deviation were imputed did not alter
the clinical or statistical significance of the results (MD -2.31 days,
95% CI -2.93 to -1.69; Analysis 3.2).
Readmissions
Seven trials (733 participants) reported hospital readmissions (
Jones 2013; Kim 2012; Lemanu 2013; Liu 2010; Lu 2014; Wang
2010; Zhao 2014). There was no statistically significant difference
in the proportion of participants requiring hospital readmissions
between enhanced recovery protocols and standard care (RR 1.40,
95% CI 0.69 to 2.87; Analysis 1.8). There was no change in the
statistical significance by using the random-effects model. There
was no evidence of heterogeneity (I2 = 0%; P = 0.84).
Costs
Four trials (282 participants) reported hospital costs (Kim 2012;
Lemanu 2013; Wang 2010; Zhao 2014). The costs were reported
in US dollars (USD) in one trial (Kim 2012), New Zealand dol-
lars (NZD) in one trial (Lemanu 2013), and Chinese renminbi
(CNY) in two trials (Wang 2010; Zhao 2014). All the currencies
were converted to USD using the conversion rates of those cur-
rencies on www.xe.com on 2 April 2015. The hospital costs were
statistically significantly lower with enhanced recovery protocols
than standard care (MD -6300 USD, 95% CI -8400 to -4200;
Analysis 1.9). There was no change in the statistical significance
by using the random-effects model. There was no evidence of het-
erogeneity (I2 = 12%; P = 0.33). The mean and standard devia-
tion were imputed from the median and P value from one trial
(Zhao 2014). Excluding this trial did not alter the clinical or sta-
tistical significance of the results (MD -6000 USD, 95% CI 8100
to 3900; Analysis 3.3).
Subgroup analysis
Of the planned subgroup analysis, we did not perform a subgroup
analysis of the different elements of enhanced recovery protocols
since there was considerable overlap between the trials in terms
of the different elements of enhanced recovery protocols that was
incorporated in the intervention arm of the trial (Table 1). None
of the trials included children, so we did not perform a subgroup
analysis of adults versus children. Amongst the different surgeries,
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only gastrectomy and liver surgery were surgeries that were assessed
in two or more trials. We could not obtain the results of the test
for subgroup differences for short-term mortality since there was
no short-term mortality after gastrectomy in the trials included in
the subgroup analysis (Analysis 2.1). The tests for subgroup dif-
ferences were not statistically significant for proportion or number
of serious adverse events. The test for subgroup differences was
statistically significant for health-related quality of life (P = 0.01)
with the enhanced recovery protocol appearing beneficial mainly
for liver surgery.
D I S C U S S I O N
Summary of main results
In this meta-analysis we found that the proportion of people with
mild adverse events, the number of mild adverse events, the length
of hospital stay and costs were lower with enhanced recovery pro-
tocols compared to standard care after major upper gastrointesti-
nal, liver and pancreatic surgery. There were no statistically signif-
icant differences in short-termmortality, the proportion of people
with serious adverse events, the number of serious adverse events,
short-term health-related quality of life, and the proportion of
people requiring readmissions. None of the trials reported long-
term mortality, medium-term health-related quality of life, time
to return to normal activity or time to return to work.
While mortality and serious adverse events are clinically more im-
portant than mild adverse events, an intervention that decreases
mild adverse events can be considered useful and can be recom-
mended if it is cost-effective. Enhanced recovery protocols reduced
the length of hospital stay and costs. This is important for the
vast majority of the healthcare funders, irrespective of whether the
healthcare is funded by the state or the patients. On this basis, en-
hanced recovery protocols appear to be a useful intervention if the
evidence is reliable. However, the quality of evidence is low and
the effect estimates observed in the trials may not be close to the
true effect of the enhanced recovery protocols compared to stan-
dard care, as discussed in the section on Quality of the evidence.
The test for subgroup differences was statistically significant for
quality of life with enhanced recovery protocols demonstrating an
improved quality of life in liver surgery, however, there are two
notes of caution. The first is that when many subgroup analyses
are performed, there is a significant chance of getting spuriously
positive results. So, the results of this subgroup analysis have to
be interpreted with caution. The second is that we do not know
whether the demonstrated increase in the quality of life in liver
surgery is clinically significant.
Overall completeness and applicability of
evidence
A variety of surgeries on the oesophagus, stomach, liver and pan-
creas were included in this review. So, this evidence is applicable in
these surgeries. However, it should be noted that only people with
good performance status and low anaesthetic risk were included
in the trials and so the evidence from this review is applicable only
to such people.
Quality of the evidence
The overall quality of the evidence is low or very low as indicated
in Summary of findings for themain comparison. The factors that
introduce bias and make the effect estimates unreliable are as fol-
lows. One of the major sources of bias in the trials included in this
review is the lack of blinding of even the healthcare providers who
assess the outcomes, including the adverse events, and make deci-
sions on hospital discharge. Despite the use of specific definitions
for adverse events being used for one trial (Barlow 2011), and pre-
defined criteria for hospital discharge for four trials (Barlow 2011;
Jones 2013; Liu 2010; Wang 2010), lack of observer blinding can
result in bias of these outcomes. This is because adverse events and
hospital stay are subjective outcomes since the criteria used for
assessment of these outcomes (even if the trials had prespecified
criteria) are subjective. Only one trial reported observer blinding
for decision on discharge (Jones 2013), while none of the trials
used observer blinding for serious adverse events. While it is dif-
ficult or even impossible to blind the participants and healthcare
providers for some elements of enhanced recovery protocols (pre-
operative education and early mobilisation), it is possible to blind
the outcome assessors for all the elements of enhanced recovery
protocols by use of a second surgical team.
Another major source of bias is attrition bias. By excluding par-
ticipants in whom the protocol was violated or who developed
complications intraoperatively, the benefits of enhanced recovery
protocols on the length of hospital stay and costs will be overes-
timated. The length of hospital stay reported in the trials did not
include the length of hospital stay during readmissions. This will
again overestimate the effect of the enhanced recovery protocol
group on the length of hospital stay and costs. If there were no
clinically significant differences in the number of people with se-
rious adverse events or readmissions, the effect estimate of the en-
hanced recovery protocol on the length of hospital stay and costs
will be shifted towards null effect. If there were more serious ad-
verse events and readmissions in the enhanced recovery protocols,
the balance of benefits and harms of enhanced recovery proto-
cols compared to standard care will again be shifted. Future trials
should include all randomised participants and perform an inten-
tion-to-treat analysis so that a reasonable estimate of the effect of
the enhanced recovery protocol can be obtained and used to guide
clinical practice. None of the studies included the organisational
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costs of implementing enhanced recovery protocols. While het-
erogeneity was noted in some of the outcomes, this was mainly in
the magnitude of effect rather than the direction of effect. Hetero-
geneity appears to be less of a threat to the validity of the results
compared to the other factors (lack of blinding of outcome asses-
sors, attrition bias, and the way that the length of hospital stay and
costs were measured). However, there is a potential for different
effects of enhanced recovery protocols in different surgeries, and
so future trials should report the effects of enhanced recovery pro-
tocols in different surgeries as subgroups.
Potential biases in the review process
We performed a thorough literature search using formal search
strategies. At least two review authors independently identified
trials for inclusion and extracted data, thus minimising errors in
these aspects. We examined the influence of our imputations us-
ing sensitivity analyses which did not alter the clinical or statis-
tical significance of the results. We were unable to explore publi-
cation bias because none of the outcomes had 10 or more trials.
However, we searched the trial registers. Since the enhanced re-
covery protocol is a relatively new intervention, we anticipate that
trials related to this topic are registered prospectively. However,
four trials are awaiting further assessment (Geubbels 2014; Jin
2013; NCT02348229; Wang 2014), and four trials are currently
ongoing (JPRN-UMIN000011572; JPRN-UMIN000014068;
NCT01766765; NCT01938313). The inclusion of these trials
may alter the conclusions of the review.
Agreements and disagreements with other
studies or reviews
This is the first systematic review to compare enhanced recovery
protocols with standard care in people undergoing major upper
gastrointestinal, liver and pancreatic surgeries. We identified three
systematic reviews with meta-analysis on the role of enhanced re-
covery protocols versus standard care in people undergoing gas-
trectomy (Chen 2015; Li 2014; Yu 2014). The authors of these
systematic reviews concluded that the length of hospital stay and
costs are reduced with enhanced recovery protocols compared to
standard care (Chen 2015; Li 2014; Yu 2014). While we observed
similar results in our systematic review, we are unable to deter-
mine the validity of the results because of the reasons stated in the
section on Quality of the evidence.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Based on low quality evidence, enhanced recovery protocols may
reduce the length of hospital stay and hospital costs (primarily
because of reduction in hospital stay) in people undergoing major
upper gastrointestinal, liver and pancreatic surgeries. However, the
validity of the results is uncertain because of the risk of bias in the
trials and the way the outcomes were measured.
Implications for research
Future RCTs should use appropriate randomisation methods,
use outcome assessor blinding, include all randomised partici-
pants, andmeasure clinical outcomes such asmortality, morbidity,
health-related quality of life and length of hospital stay (including
any readmissions for procedure related complications) for at least
three months to one year to determine the utility of enhanced re-
covery protocols on people undergoing major upper gastrointesti-
nal, liver and pancreatic surgeries. Since the impact of enhanced
recovery protocols may be different between different surgeries,
the results of different surgeries should be reported separately as
subgroup analyses.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Barlow 2011
Methods Randomised controlled trial
Participants Country: UK.
Number randomised: 121
Post-randomisation drop-outs: 0 (0%)
Revised sample size: 121
Average age: 64 years
Females: 38 (31.4%)
Inclusion criteria
1. All adult patients admitted with a suspected upper gastrointestinal malignancy and
referred for major elective surgery (oesophagectomy, gastrectomy and pancreatectomy)
Exclusion criteria
1. Age under 18 years
2. Unable or unwilling to give informed consent
3. Pregnancy
4. Preoperative infection
5. Previous intestinal surgery resulting in residual small intestine length of less than
100 cm
Interventions Participants were randomly assigned to two groups
Group 1: enhanced recovery protocol (n = 64)
Further details: Early enteral nutrition delivered via a needle catheter jejunostomy
Group 2: standard care (n = 57)
Outcomes The outcomes reported were short-term mortality, serious adverse events, mild adverse
events and length of hospital stay
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomisation was stratified within each cen-
tre, and the randomisation sequence was generated by
computer in permuted blocks of 30”
Allocation concealment (selection bias) Low risk Quote: “The code was kept in opaque, sealed envelopes
labelled with sequential study numbers in a locked box
at the co-ordinating research site”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “This was an unblinded study”
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Barlow 2011 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “This was an unblinded study”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: There were no post-randomisation drop-outs
Selective reporting (reporting bias) Low risk Comment: All important outcomes were reported
Other bias Low risk Quote: “The trial was funded by grant to Dr Barlow:
”Leading Practice through research“ from theTheHealth
Foundation, London, UK”
Jones 2013
Methods Randomised controlled trial
Participants Country: UK.
Number randomised: 104
Post-randomisation drop-outs: 13 (12.5%)
Revised sample size: 91
Average age: 66 years
Females: 37 (40.7%)
Inclusion criteria
All patients presenting for open liver surgery
Exclusion criteria
1. Operation was entirely laparoscopic
2. Patient needed a second concomitant procedure (e.g. bile duct repair)
3. Found to be inoperable.
4. Unable to consent
Interventions Participants were randomly assigned to two groups
Group 1: enhanced recovery protocol (n = 46)
Further details:
Preoperatively: education
Postoperatively: early mobilisation and early oral feeding according to a specific schedule
Group 2: standard care (n = 45)
Outcomes The outcomes reported were short-term mortality, serious adverse events, health-related
quality of life, mild adverse events, length of hospital stay and readmissions
Notes Authors provided additional information in January 2015
Reasons for post-randomisation drop-outs: 13 due to changes in their oncological staging
(they either underwent additional procedures, were inoperable at the time of surgery, or
had a laparoscopic resection)
Risk of bias
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Jones 2013 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The randomization sequence of group allocation
bymeans of brown opaque envelopes was generated by an
independent statistician from the University of Surrey”
Allocation concealment (selection bias) Low risk Quote: “The randomization sequence of group allocation
bymeans of brown opaque envelopes was generated by an
independent statistician from the University of Surrey”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “no blinding”
Comment: email reply
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “only assessor for fitness for discharge was
blinded, meaning Length of stay was blinded”
Comment: email reply
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “Thirteenpatientswerewithdrawn after random-
ization because of changes to their original oncological
staging”
Selective reporting (reporting bias) Low risk Comment: All important outcomes were reported
Other bias Low risk Quote: “Thanks also go toGUTS (GuildfordUndetected
Tumour Screening) and LCSA (Liver Cancer Surgery
Appeal) charities who kindly provided grants helping to
fund the trial”
Kim 2012
Methods Randomised controlled trial
Participants Country: Korea
Number randomised: 47
Post-randomisation drop-outs: 3 (6.4%)
Revised sample size: 44
Average age: 55 years
Females: 16 (36.4%)
Inclusion criteria
1. Gastric cancer that could be treated with a laparoscopic distal gastrectomy
2. Pathological confirmation of gastric adenocarcinoma
3. Preoperative cancer stage of T1N0M0, T1N1M0 or T2N0M0
4. Location of the lesion in the lower half of the stomach
Exclusion criteria
Factors that might impede a fast recovery:
1. pregnancy
2. inflammatory bowel disease
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Kim 2012 (Continued)
3. chronic renal disease
4. chronic liver disease
5. cardiopulmonary dysfunction
6. complicated diabetes
7. the use of anticholinergic medications
8. ASA (The American Society of Anaesthesiologists) > 2
9. ECOG (Eastern Cooperative Oncology Group performance status) grade > 3
Interventions Participants were randomly assigned to two groups
Group 1: enhanced recovery protocol (n = 22)
Further details:
Preoperatively: education
Postoperatively: pain relief, early mobilisation and early oral feeding according to a
specific schedule
Group 2: standard care (n = 22)
Outcomes The outcomes reported were short-term mortality, serious adverse events, health-related
quality of life, mild adverse events, length of hospital stay, readmissions and costs
Notes Reasons for post-randomisation drop-outs: protocol violation (1); surgeon suspected an
insecure anastomosis (2) - both developed anastomotic stricture and required endoscopic
stenting postoperatively
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomisation was performed by drawing lots
under stratification for gender by the co-ordinator”
Allocation concealment (selection bias) Low risk Quote: “Randomisation was performed by drawing lots
under stratification for gender by the co-ordinator”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “The nurses and physicians were told the result
of the randomisation”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “The nurses and physicians were told the result
of the randomisation”
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: There were post-randomisation drop-outs
Selective reporting (reporting bias) Low risk Comment: All important outcomes were reported
Other bias High risk Quote: “The LAPD was supplied from B. Braun Korea
Company just for this study”
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Lemanu 2013
Methods Randomised controlled trial
Participants Country: New Zealand.
Number randomised: 106
Post-randomisation drop-outs: 28 (26.4%)
Revised sample size: 78
Average age: 44 years
Females: 55 (70.5%)
Inclusion criteria
All patients offered laparoscopic sleeve gastrectomy
Exclusion criteria
Patients having LSG as a revisional bariatric procedure
Interventions Participants were randomly assigned to two groups
Group 1: enhanced recovery protocol (n = 40)
Further details:
Preoperatively: education
Postoperatively: pain relief, early mobilisation and early oral feeding according to a
specific schedule
Group 2: standard care (n = 38)
Outcomes The outcomes reported were short-term mortality, serious adverse events, mild adverse
events, mild adverse events, length of hospital stay and readmissions
Notes Reasons for post-randomisation drop-outs: Surgery changed to another site or cancelled
or other miscellaneous reasons
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization was performed by an indepen-
dent researcher not involved in patient recruitment or
outcome assessment using a computerized random-num-
ber generator”
Allocation concealment (selection bias) Low risk Quote: “Group allocations were placed in sequentially
numbered opaque sealed envelopes”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: This information was not available
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: This information was not available
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: There were post-randomisation drop-outs
27Enhanced recovery protocols for major upper gastrointestinal, liver and pancreatic surgery (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Lemanu 2013 (Continued)
Selective reporting (reporting bias) High risk Comment: Complications were not reported adequately
Other bias Low risk Quote: “This study required no external sources of fund-
ing”
Liu 2010
Methods Randomised controlled trial
Participants Country: China
Number randomised: 63
Post-randomisation drop-outs: 0 (0%)
Revised sample size: 63
Average age: 61 years
Females: 29 (46%)
Inclusion criteria
Patients undergoing gastrectomy for gastric cancer
Exclusion criteria
1. Patients with reluctance to discharge early
2. Presence of other organ dysfunction such as lung and kidney
3. Abnormal clinical test results
4. Preoperative chemotherapy
5. Preoperative radiotherapy
Interventions Participants were randomly assigned to two groups
Group 1: enhanced recovery protocol (n = 33)
Further details:
Postoperatively: early mobilisation and early oral feeding
Group 2: standard care (n = 30)
Outcomes The outcomes reported were short-term mortality, serious adverse events, mild adverse
events, length of hospital stay and readmissions
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: This information was not available
Allocation concealment (selection bias) Unclear risk Quote: “Randomization was performed using opaque
sealed envelopes”
Comment: Further details were not available
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Liu 2010 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “As with other fast-track trials, it was not possible
to blind this study”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “As with other fast-track trials, it was not possible
to blind this study”
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: There were post-randomisation drop-outs
Selective reporting (reporting bias) High risk Comment: Complications were not reported adequately
Other bias Unclear risk Comment: Information on source of funding was not
available
Lu 2014
Methods Randomised controlled trial
Participants Country: China.
Number randomised: 297
Post-randomisation drop-outs: not stated
Revised sample size: 297
Average age: 53 years
Females: 53 (17.8%)
Inclusion criteria
1. Patients with hepatocellular carcinoma (diagnosed and pathologically confirmed)
undergoing surgery
2. Preoperative assessment suggested no existing physical illness, Child Pugh grade
of A or B, no tumour metastasis and limited partial liver resection
3. No preoperative or intraoperative transcatheter hepatic arterial
chemoembolisation or radiofrequency ablation
4. Tumour completely resected
Interventions Participants were randomly assigned to two groups
Group 1: enhanced recovery protocol (n = 135)
Further details:
Postoperatively: early mobilisation and early oral feeding
Group 2: standard care (n = 162)
Outcomes The outcomes reported were short-term mortality, serious adverse events, mild adverse
events, length of hospital stay and readmissions
Notes
Risk of bias
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Lu 2014 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: This information was not available
Allocation concealment (selection bias) Unclear risk Comment: This information was not available
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “This trial was randomized and single-blinded”
Comment: The group that was blinded was not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “This trial was randomized and single-blinded”
Comment: The group that was blinded was not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: This information was not available
Selective reporting (reporting bias) High risk Comment: Complications were not reported adequately
Other bias Unclear risk Comment: Information on source of funding was not
available
Miyachi 2013
Methods Randomised controlled trial
Participants Country: Japan
Number randomised: 43
Post-randomisation drop-outs: 10 (23.3%)
Revised sample size: 33
Average age: 60 years
Females: 13 (39.4%)
Inclusion criteria
All patients aged 40 to 75 who underwent distal gastrectomy for gastric cancer
Exclusion criteria
1. Distant metastases
2. Undernutrition (serum albumin < 3.5 g.dL)
3. Decline in performance status (greater than or equal to 2)
4. Pyloric stenosis for cancer
Interventions Participants were randomly assigned to two groups
Group 1: enhanced recovery protocol (n = 15)
Further details: Cystine (700 mg) and Theanine (280 mg) administered orally to patients
with a small amount of water from 4 days before surgery to 5 days after surgery, including
the day of the procedure
Group 2: standard care (n = 18)
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Miyachi 2013 (Continued)
Outcomes None of the outcomes of interest were reported
Notes Reasons for post-randomisation drop-outs: Onset of herpes zoster before the procedure
(1), excessive intraoperative haemorrhage (> 600 mL) (2), injury to the left hepatic
artery during surgery (1), changes in surgical procedure (2), metastasis to the peritoneum
confirmed during surgery (1) and withdrawal of consent (3)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: This information was not available
Allocation concealment (selection bias) Unclear risk Quote: “Patients were assigned to 1 of 2 groups using
the sealed- envelope method and a randomized, single-
blind, parallel- group study was performed”
Comment: Further details were not available
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “Patients were assigned to 1 of 2 groups using
the sealed- envelope method and a randomized, single-
blind, parallel- group study was performed”
Comment: This trial states single blinding and a placebo
was used but it is not clear who was blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “Patients were assigned to 1 of 2 groups using
the sealed- envelope method and a randomized, single-
blind, parallel- group study was performed”
Comment: This trial states single blinding and a placebo
was used but it is not clear who was blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: There were post-randomisation drop-outs
Selective reporting (reporting bias) High risk Comment: Complications were not reported adequately
Other bias Unclear risk Comment: Information on source of funding was not
available
Ni 2013
Methods Randomised controlled trial
Participants Country: China
Number randomised: 160
Post-randomisation drop-outs: 0 (0%)
Revised sample size: 160
Average age: 49 years
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Ni 2013 (Continued)
Females: 35 (21.9%)
Inclusion criteria
1. Elective partial hepatectomy for liver cancer
2. No major surgical concomitant surgical procedures such as a bowel or bile duct
resection
3. Tumours either in the right or left hemiliver with the extent of partial
hepatectomy being a hemihepatectomy or less
4. Child-Pugh Class A/B liver functional status
Exclusion criteria
1. Age less than 16 or over 65
2. Benign liver tumour or metastatic liver cancer
3. Severe concomitant medical disease
4. Combined with other surgery
5. Liver re-resection
6. Bilobar tumour
7. Declined to participate
Interventions Participants were randomly assigned to two groups
Group 1: enhanced recovery protocol (n = 80)
Further details:
Preoperatively: education
Postoperatively: pain relief, early mobilisation and early oral feeding according to a
specific schedule
Group 2: standard care (n = 80)
Outcomes The outcomes reported were short-term mortality, serious adverse events, health-related
quality of life, mild adverse events and length of hospital stay
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The patients were assigned either to the FTS
group or to theCS group by computer-generated random
numbers ”
Allocation concealment (selection bias) Unclear risk Comment: This information was not available
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: This information was not available
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: This information was not available
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Ni 2013 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: There were no post-randomisation drop-outs
Selective reporting (reporting bias) Low risk Comment: All important outcomes were reported
Other bias Low risk Quote: “This study is supported by the StateKey In-
fectious Disease Project of China (2012ZX10002010,
2012ZX10002016), Science Fund for Creative Research
Groups, NSFC, China 81221061, Nursing Research
Fund of EHBH (12HL001)”
Wang 2010
Methods Randomised controlled trial
Participants Country: China
Number randomised: 94
Post-randomisation drop-outs: 2 (2.1%)
Revised sample size: 92
Average age: 58 years
Females: 31 (33.7%)
Inclusion criteria
1. Clinical diagnosis of gastric cancer
2. Patients younger than 80
3. No preoperative chemoradiotherapy
Exclusion criteria
1. Primary diabetes mellitus
2. Impaired glucose tolerance
3. Primary hepatonephric diseases
4. Primary cardio-cerebral diseases
5. Severe obesity or BMI > 30 Kg/m2
6. Severe malnutrition BMI < 15 Kg/m2
7. Hyperthyroidism
8. Hypothyroidism
Interventions Participants were randomly assigned to two groups
Group 1: enhanced recovery protocol (n = 45)
Further details:
Preoperatively: education
Postoperatively: pain relief, early mobilisation and early oral feeding according to a
specific schedule
Group 2: standard care (n = 47)
Outcomes The outcomes reported were short-termmortality,mild adverse events, length of hospital
stay, readmissions and costs
Notes Reasons for post-randomisation drop-outs: 2 patients withdrew their consent
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Wang 2010 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: This information was not available
Allocation concealment (selection bias) Unclear risk Comment: This information was not available
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: This information was not available
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: This information was not available
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “Two patients who withdrew their consent in the
FTS group were excluded from the study”
Comment: The reason for withdrawal was not reported
Selective reporting (reporting bias) High risk Comment: Complications were not reported adequately
Other bias Unclear risk Comment: Information on source of funding was not
available
Zhao 2014
Methods Randomised controlled trial
Participants Country: China
Number randomised: 80
Post-randomisation drop-outs: 12 (15%)
Revised sample size: 68
Average age: 57 years
Females: 16 (23.5%)
Inclusion criteria
Patients with oesophageal cancer undergoing oesophagectomy
Exclusion criteria
1. A tumour of the hypopharynx
2. Tumour of the cervical oesophagus
3. Serious comorbidity
4. ASA 3 and 4
5. Preoperative distant metastasis
6. Perioperative instability.
7. Moderate risk factors e.g. previous coronary artery bypass graft, mild chronic
obstructive pulmonary disease, Karnofsky index less than 60, BMI less than 18.5 kg/m2
8. Age of 65 to 75 with hypertension, diabetes or vascular disease
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Zhao 2014 (Continued)
Interventions Participants were randomly assigned to two groups
Group 1: enhanced recovery protocol (n = 34)
Further details:
Preoperatively: education
Postoperatively: pain relief according to a specific schedule
Group 2: standard care (n = 34)
Outcomes The outcomes reportedwere serious adverse events,mild adverse events, length of hospital
stay, readmissions and costs
Notes Reasons for post-randomisation drop-outs: Protocol violation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Enrolled patients were randomly assigned to two
groups using computer-generated randomnumbers (ran-
dom digits from 0 to 99)”
Allocation concealment (selection bias) Low risk Quote: “The investigators who designed the study pre-
pared the envelopes and assigned participants to their
groups but had no contact with the patients throughout
the study. The investigator who recruited the patients,
administered the interventions, and evaluated the out-
comes was not involved in the randomization process”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: This information was not available
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: This information was not available
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: There were post-randomisation drop-outs
Selective reporting (reporting bias) High risk Comment: Complications were not reported adequately
Other bias Low risk Quote: Science Foundation of Heilongjiang health dept,
the science foundation of Heilongjiang Education dept
and the China postdoctoral Science foundation
BMI: body mass index; CS: conventional surgery; FTS: fast track surgery; LAPD: local anaesthesia pump device; LSG: laparoscopic
sleeve gastrectomy.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Cheifetz 2010 Not specific to major upper gastrointestinal, liver or pancreatic surgery
Dejong 2014 Not a randomised controlled trial
Feldman 2014 Not a randomised controlled trial
Gillissen 2011 Comparison between two enhanced recovery protocols
Hendry 2010 Not a randomised controlled trial
Hubner 2012 Not specific to major upper gastrointestinal, liver or pancreatic surgery
Revie 2012 Not a randomised controlled trial
Sahoo 2014 Not a randomised controlled trial
Serclova 2009 Not major upper gastrointestinal, liver or pancreatic surgery
Strobel 2013 Comment on an included study (Jones 2013)
Wattchow 2009 Not major upper gastrointestinal, liver or pancreatic surgery
Characteristics of studies awaiting assessment [ordered by study ID]
Geubbels 2014
Methods Randomised controlled trial
Participants Patients undergoing laparoscopic Roux-en-Y gastric bypass surgery
Interventions Fast-track surgery
Outcomes Complication rate (no raw data)
Notes Unclear if enhanced recovery protocol, as per definition used in the review, was used
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Jin 2013
Methods Randomised controlled trial
Participants Patients undergoing pancreaticoduodenectomy
Interventions Fast-track surgery
Outcomes Complication rate, length of hospital stay (no raw data)
Notes Unclear if enhanced recovery protocol, as per definition used in the review, was used
NCT02348229
Methods Randomised controlled trial
Participants Patients undergoing laparoscopic assisted gastrectomy
Interventions Enhanced recovery protocol
Outcomes Length of hospital stay (no results reported)
Notes Unclear if enhanced recovery protocol, as per definition used in the review, was used
Wang 2014
Methods Randomised controlled trial
Participants Patients undergoing gastrectomy
Interventions Fast-track surgery
Outcomes Complication rate, length of hospital stay and costs (number of people allocated to each group was not reported)
Notes Unclear if enhanced recovery protocol, as per definition used in the review, was used
Characteristics of ongoing studies [ordered by study ID]
JPRN-UMIN000011572
Trial name or title JPRN-UMIN000011572
Methods Randomised controlled trial
Participants Patients requiring pancreaticoduodenectomy
Interventions Enhanced recovery after protocol
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JPRN-UMIN000011572 (Continued)
Outcomes Length of postoperative hospital stay, postoperative morbidity and mortality, medical cost and safety
Starting date May 2014
Contact information Ryuichi Yoshida (ryuichi-yoshida@md.okayama-u.ac.jp)
Notes
JPRN-UMIN000014068
Trial name or title JPRN-UMIN000014068
Methods Randomised controlled trial
Participants Patients requiring gastrectomy
Interventions Enhanced recovery after protocol
Outcomes Length of postoperative hospital stay, postoperative morbidity and mortality
Starting date September 2013
Contact information Kazuhisa Uchiyama (uchi@poh.osaka-med.ac.jp)
Notes
NCT01766765
Trial name or title NCT01766765
Methods Randomised controlled trial
Participants Patients requiring laparoscopic gastrectomy
Interventions Enhanced recovery after protocol
Outcomes Length of postoperative hospital stay and mortality
Starting date April 2013
Contact information Qi Mao (maoqimdphd@gmail.com)
Notes
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NCT01938313
Trial name or title NCT01938313
Methods Randomised controlled trial
Participants Patients requiring laparoscopic gastrectomy
Interventions Enhanced recovery after protocol
Outcomes Length of postoperative hospital stay, postoperative complications and quality of life
Starting date August 2012
Contact information Hyung-Ho Kim (hhkim@snubh.org)
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. Enhanced recovery protocol versus standard care
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Short-term mortality 7 868 Risk Ratio (M-H, Fixed, 95% CI) 2.79 [0.44, 17.73]
2 Serious adverse events
(proportion)
2 341 Risk Ratio (M-H, Fixed, 95% CI) 5.57 [0.68, 45.89]
3 Serious adverse events (number) 7 859 Rate Ratio (Fixed, 95% CI) 0.72 [0.45, 1.13]
4 Health-related quality of life 4 373 Std. Mean Difference (IV, Random, 95% CI) 0.29 [-0.04, 0.62]
5 Mild adverse events (proportion) 4 525 Risk Ratio (M-H, Fixed, 95% CI) 0.58 [0.39, 0.85]
6 Mild adverse events (number) 9 1014 Rate Ratio (Fixed, 95% CI) 0.52 [0.39, 0.70]
7 Length of hospital stay 9 1014 Mean Difference (IV, Fixed, 95% CI) -2.19 [-2.53, -1.85]
8 Readmissions 7 733 Risk Ratio (M-H, Fixed, 95% CI) 1.40 [0.69, 2.87]
9 Costs 4 282 Mean Difference (IV, Fixed, 95% CI) -0.63 [-0.84, -0.42]
Comparison 2. Enhanced recovery protocol versus standard care (subgroup analysis)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Short-term mortality 6 747 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.06, 15.17]
1.1 Oesophagectomy 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Gastrectomy 3 548 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.06, 15.17]
1.3 Liver surgery 3 199 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Serious adverse events
(proportion)
2 341 Risk Ratio (M-H, Fixed, 95% CI) 5.57 [0.68, 45.89]
2.1 Oesophagectomy 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Gastrectomy 1 44 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.13, 69.87]
2.3 Liver surgery 1 297 Risk Ratio (M-H, Fixed, 95% CI) 8.39 [0.44, 161.01]
3 Serious adverse events (number) 6 Rate Ratio (Fixed, 95% CI) 0.87 [0.53, 1.43]
3.1 Oesophagectomy 1 Rate Ratio (Fixed, 95% CI) 0.33 [0.01, 8.12]
3.2 Gastrectomy 2 Rate Ratio (Fixed, 95% CI) 1.10 [0.35, 3.49]
3.3 Liver surgery 3 Rate Ratio (Fixed, 95% CI) 0.84 [0.48, 1.48]
4 Health-related quality of life 4 373 Std. Mean Difference (IV, Random, 95% CI) 0.29 [-0.04, 0.62]
4.1 Oesophagectomy 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Gastrectomy 2 122 Std. Mean Difference (IV, Random, 95% CI) -0.03 [-0.39, 0.32]
4.3 Liver surgery 2 251 Std. Mean Difference (IV, Random, 95% CI) 0.52 [0.27, 0.77]
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Comparison 3. Enhanced recovery protocol versus standard care (sensitivity analysis)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Health-related quality of life 3 282 Std. Mean Difference (IV, Random, 95% CI) 0.17 [-0.19, 0.53]
2 Length of hospital stay 3 267 Mean Difference (IV, Fixed, 95% CI) -2.31 [-2.93, -1.69]
3 Costs 3 214 Mean Difference (IV, Fixed, 95% CI) -0.60 [-0.81, -0.39]
Analysis 1.1. Comparison 1 Enhanced recovery protocol versus standard care, Outcome 1 Short-term
mortality.
Review: Enhanced recovery protocols for major upper gastrointestinal, liver and pancreatic surgery
Comparison: 1 Enhanced recovery protocol versus standard care
Outcome: 1 Short-term mortality
Study or subgroup
Enh.
recovery
protocol Standard care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Barlow 2011 3/64 0/57 34.3 % 6.25 [ 0.33, 118.38 ]
Jones 2013 1/46 1/45 65.7 % 0.98 [ 0.06, 15.17 ]
Kim 2012 0/22 0/22 Not estimable
Liu 2010 0/33 0/30 Not estimable
Lu 2014 0/135 0/162 Not estimable
Ni 2013 0/80 0/80 Not estimable
Wang 2010 0/45 0/47 Not estimable
Total (95% CI) 425 443 100.0 % 2.79 [ 0.44, 17.73 ]
Total events: 4 (Enh. recovery protocol), 1 (Standard care)
Heterogeneity: Chi2 = 0.85, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 1.09 (P = 0.28)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours enh. rec. prot. Favours standard care
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Analysis 1.2. Comparison 1 Enhanced recovery protocol versus standard care, Outcome 2 Serious adverse
events (proportion).
Review: Enhanced recovery protocols for major upper gastrointestinal, liver and pancreatic surgery
Comparison: 1 Enhanced recovery protocol versus standard care
Outcome: 2 Serious adverse events (proportion)
Study or subgroup
Enh.
recovery
protocol Standard care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kim 2012 1/22 0/22 52.4 % 3.00 [ 0.13, 69.87 ]
Lu 2014 3/135 0/162 47.6 % 8.39 [ 0.44, 161.01 ]
Total (95% CI) 157 184 100.0 % 5.57 [ 0.68, 45.89 ]
Total events: 4 (Enh. recovery protocol), 0 (Standard care)
Heterogeneity: Chi2 = 0.22, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 1.60 (P = 0.11)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours enh. rec. prot. Favours standard care
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Analysis 1.3. Comparison 1 Enhanced recovery protocol versus standard care, Outcome 3 Serious adverse
events (number).
Review: Enhanced recovery protocols for major upper gastrointestinal, liver and pancreatic surgery
Comparison: 1 Enhanced recovery protocol versus standard care
Outcome: 3 Serious adverse events (number)
Study or subgroup
Enh.
recovery
protocol Standard care log [Rate Ratio] Rate Ratio Weight Rate Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Barlow 2011 64 57 -1.29 (0.57) 16.7 % 0.28 [ 0.09, 0.84 ]
Jones 2013 46 45 -0.46 (0.43) 29.3 % 0.63 [ 0.27, 1.47 ]
Kim 2012 22 22 1.1 (1.63) 2.0 % 3.00 [ 0.12, 73.31 ]
Lemanu 2013 40 38 -0.05 (0.63) 13.7 % 0.95 [ 0.28, 3.27 ]
Lu 2014 135 162 2.13 (1.51) 2.4 % 8.41 [ 0.44, 162.32 ]
Ni 2013 80 80 -0.08 (0.4) 33.9 % 0.92 [ 0.42, 2.02 ]
Zhao 2014 34 34 -1.1 (1.63) 2.0 % 0.33 [ 0.01, 8.12 ]
Total (95% CI) 421 438 100.0 % 0.72 [ 0.45, 1.13 ]
Heterogeneity: Chi2 = 7.16, df = 6 (P = 0.31); I2 =16%
Test for overall effect: Z = 1.43 (P = 0.15)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours enh. rec. prot. Favours standard care
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Analysis 1.4. Comparison 1 Enhanced recovery protocol versus standard care, Outcome 4 Health-related
quality of life.
Review: Enhanced recovery protocols for major upper gastrointestinal, liver and pancreatic surgery
Comparison: 1 Enhanced recovery protocol versus standard care
Outcome: 4 Health-related quality of life
Study or subgroup
Enh.
recovery
protocol Standard care
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Jones 2013 46 37.2 (2.4) 45 35.6 (2.4) 25.6 % 0.66 [ 0.24, 1.08 ]
Kim 2012 22 8.9 (2.46) 22 9.28 (2.4) 18.2 % -0.15 [ -0.75, 0.44 ]
Lemanu 2013 40 80.5 (10.2) 38 80.1 (10.1) 24.5 % 0.04 [ -0.41, 0.48 ]
Ni 2013 80 101.2 (13) 80 93.4 (21.4) 31.6 % 0.44 [ 0.12, 0.75 ]
Total (95% CI) 188 185 100.0 % 0.29 [ -0.04, 0.62 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 7.03, df = 3 (P = 0.07); I2 =57%
Test for overall effect: Z = 1.73 (P = 0.084)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours standard care Favours enh. rec. prot.
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Analysis 1.5. Comparison 1 Enhanced recovery protocol versus standard care, Outcome 5 Mild adverse
events (proportion).
Review: Enhanced recovery protocols for major upper gastrointestinal, liver and pancreatic surgery
Comparison: 1 Enhanced recovery protocol versus standard care
Outcome: 5 Mild adverse events (proportion)
Study or subgroup
Enh.
recovery
protocol Standard care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Barlow 2011 21/64 29/57 59.1 % 0.64 [ 0.42, 0.99 ]
Kim 2012 2/22 4/22 7.7 % 0.50 [ 0.10, 2.45 ]
Liu 2010 4/33 6/30 12.1 % 0.61 [ 0.19, 1.94 ]
Lu 2014 4/135 12/162 21.0 % 0.40 [ 0.13, 1.21 ]
Total (95% CI) 254 271 100.0 % 0.58 [ 0.39, 0.85 ]
Total events: 31 (Enh. recovery protocol), 51 (Standard care)
Heterogeneity: Chi2 = 0.71, df = 3 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 2.83 (P = 0.0047)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours enh. rec. prot. Favours standard care
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Analysis 1.6. Comparison 1 Enhanced recovery protocol versus standard care, Outcome 6 Mild adverse
events (number).
Review: Enhanced recovery protocols for major upper gastrointestinal, liver and pancreatic surgery
Comparison: 1 Enhanced recovery protocol versus standard care
Outcome: 6 Mild adverse events (number)
Study or subgroup
Enh.
recovery
protocol Standard care log [Rate Ratio] Rate Ratio Weight Rate Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Barlow 2011 64 57 -0.9 (0.24) 39.9 % 0.41 [ 0.25, 0.65 ]
Jones 2013 46 45 -1.05 (0.52) 8.5 % 0.35 [ 0.13, 0.97 ]
Kim 2012 22 22 -0.69 (0.87) 3.0 % 0.50 [ 0.09, 2.76 ]
Lemanu 2013 40 38 0.46 (0.73) 4.3 % 1.58 [ 0.38, 6.62 ]
Liu 2010 33 30 -0.5 (0.65) 5.4 % 0.61 [ 0.17, 2.17 ]
Lu 2014 135 162 -0.69 (0.53) 8.2 % 0.50 [ 0.18, 1.42 ]
Ni 2013 80 80 -0.69 (0.35) 18.7 % 0.50 [ 0.25, 1.00 ]
Wang 2010 45 47 0.29 (0.5) 9.2 % 1.34 [ 0.50, 3.56 ]
Zhao 2014 34 34 -0.41 (0.91) 2.8 % 0.66 [ 0.11, 3.95 ]
Total (95% CI) 499 515 100.0 % 0.52 [ 0.39, 0.70 ]
Heterogeneity: Chi2 = 7.67, df = 8 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 4.27 (P = 0.000020)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours enh. rec. prot. Favours standard care
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Analysis 1.7. Comparison 1 Enhanced recovery protocol versus standard care, Outcome 7 Length of
hospital stay.
Review: Enhanced recovery protocols for major upper gastrointestinal, liver and pancreatic surgery
Comparison: 1 Enhanced recovery protocol versus standard care
Outcome: 7 Length of hospital stay
Study or subgroup
Enh.
recovery
protocol Standard care
Mean
Difference Weight
Mean
Difference
N Mean(SD)[days] N Mean(SD)[days] IV,Fixed,95% CI IV,Fixed,95% CI
Barlow 2011 64 16 (12.2) 57 19 (14.9) 0.5 % -3.00 [ -7.89, 1.89 ]
Jones 2013 46 4 (2.7) 45 7 (2.7) 9.5 % -3.00 [ -4.11, -1.89 ]
Kim 2012 22 5.36 (1.46) 22 7.95 (1.98) 11.1 % -2.59 [ -3.62, -1.56 ]
Lemanu 2013 40 1 (2.7) 38 2 (1.4) 13.0 % -1.00 [ -1.95, -0.05 ]
Liu 2010 33 6.2 (1.9) 30 9.8 (2.8) 8.2 % -3.60 [ -4.79, -2.41 ]
Lu 2014 135 10 (4.1) 162 13 (5.4) 10.0 % -3.00 [ -4.08, -1.92 ]
Ni 2013 80 6.9 (2.8) 80 8 (3.7) 11.3 % -1.10 [ -2.12, -0.08 ]
Wang 2010 45 6 (1.4) 47 8 (1.4) 35.7 % -2.00 [ -2.57, -1.43 ]
Zhao 2014 34 7.15 (8.4) 34 12.52 (8.4) 0.7 % -5.37 [ -9.36, -1.38 ]
Total (95% CI) 499 515 100.0 % -2.19 [ -2.53, -1.85 ]
Heterogeneity: Chi2 = 23.58, df = 8 (P = 0.003); I2 =66%
Test for overall effect: Z = 12.55 (P < 0.00001)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
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Analysis 1.8. Comparison 1 Enhanced recovery protocol versus standard care, Outcome 8 Readmissions.
Review: Enhanced recovery protocols for major upper gastrointestinal, liver and pancreatic surgery
Comparison: 1 Enhanced recovery protocol versus standard care
Outcome: 8 Readmissions
Study or subgroup
Enh.
recovery
protocol Standard care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Jones 2013 2/46 0/45 4.5 % 4.89 [ 0.24, 99.18 ]
Kim 2012 1/22 0/22 4.5 % 3.00 [ 0.13, 69.87 ]
Lemanu 2013 8/40 8/38 73.2 % 0.95 [ 0.40, 2.28 ]
Liu 2010 1/33 0/30 4.7 % 2.74 [ 0.12, 64.69 ]
Lu 2014 0/135 0/162 Not estimable
Wang 2010 1/45 1/47 8.7 % 1.04 [ 0.07, 16.20 ]
Zhao 2014 1/34 0/34 4.5 % 3.00 [ 0.13, 71.15 ]
Total (95% CI) 355 378 100.0 % 1.40 [ 0.69, 2.87 ]
Total events: 14 (Enh. recovery protocol), 9 (Standard care)
Heterogeneity: Chi2 = 2.09, df = 5 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 0.93 (P = 0.35)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours enh. rec. prot. Favours standard care
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Analysis 1.9. Comparison 1 Enhanced recovery protocol versus standard care, Outcome 9 Costs.
Review: Enhanced recovery protocols for major upper gastrointestinal, liver and pancreatic surgery
Comparison: 1 Enhanced recovery protocol versus standard care
Outcome: 9 Costs
Study or subgroup
Enh.
recovery
protocol Standard care
Mean
Difference Weight
Mean
Difference
N
Mean(SD)[,000
USD] N
Mean(SD)[,000
USD] IV,Fixed,95% CI IV,Fixed,95% CI
Kim 2012 22 7.4543 (0.7058) 22 7.77 (0.9342) 18.2 % -0.32 [ -0.81, 0.17 ]
Lemanu 2013 40 11.127 (9.819) 38 11.67 (10.7175) 0.2 % -0.55 [ -5.12, 4.02 ]
Wang 2010 4.354292 (0.585437) 45 47 5.02 (0.582165) 76.5 % -0.67 [ -0.91, -0.43 ]
Zhao 2014 5.141196 (1.956553) 34 34 6.4 (1.956553) 5.0 % -1.26 [ -2.19, -0.33 ]
Total (95% CI) 141 141 100.0 % -0.63 [ -0.84, -0.42 ]
Heterogeneity: Chi2 = 3.41, df = 3 (P = 0.33); I2 =12%
Test for overall effect: Z = 5.94 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Enhanced recovery protocol versus standard care (subgroup analysis),
Outcome 1 Short-term mortality.
Review: Enhanced recovery protocols for major upper gastrointestinal, liver and pancreatic surgery
Comparison: 2 Enhanced recovery protocol versus standard care (subgroup analysis)
Outcome: 1 Short-term mortality
Study or subgroup
Enh.
recovery
protocol Standard care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Oesophagectomy
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Enh. recovery protocol), 0 (Standard care)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Gastrectomy
Jones 2013 1/46 1/45 100.0 % 0.98 [ 0.06, 15.17 ]
Lu 2014 0/135 0/162 Not estimable
Ni 2013 0/80 0/80 Not estimable
Subtotal (95% CI) 261 287 100.0 % 0.98 [ 0.06, 15.17 ]
Total events: 1 (Enh. recovery protocol), 1 (Standard care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.99)
3 Liver surgery
Kim 2012 0/22 0/22 Not estimable
Liu 2010 0/33 0/30 Not estimable
Wang 2010 0/45 0/47 Not estimable
Subtotal (95% CI) 100 99 Not estimable
Total events: 0 (Enh. recovery protocol), 0 (Standard care)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 361 386 100.0 % 0.98 [ 0.06, 15.17 ]
Total events: 1 (Enh. recovery protocol), 1 (Standard care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.99)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 2.2. Comparison 2 Enhanced recovery protocol versus standard care (subgroup analysis),
Outcome 2 Serious adverse events (proportion).
Review: Enhanced recovery protocols for major upper gastrointestinal, liver and pancreatic surgery
Comparison: 2 Enhanced recovery protocol versus standard care (subgroup analysis)
Outcome: 2 Serious adverse events (proportion)
Study or subgroup
Enh.
recovery
protocol Standard care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Oesophagectomy
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Enh. recovery protocol), 0 (Standard care)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Gastrectomy
Kim 2012 1/22 0/22 52.4 % 3.00 [ 0.13, 69.87 ]
Subtotal (95% CI) 22 22 52.4 % 3.00 [ 0.13, 69.87 ]
Total events: 1 (Enh. recovery protocol), 0 (Standard care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.49)
3 Liver surgery
Lu 2014 3/135 0/162 47.6 % 8.39 [ 0.44, 161.01 ]
Subtotal (95% CI) 135 162 47.6 % 8.39 [ 0.44, 161.01 ]
Total events: 3 (Enh. recovery protocol), 0 (Standard care)
Heterogeneity: not applicable
Test for overall effect: Z = 1.41 (P = 0.16)
Total (95% CI) 157 184 100.0 % 5.57 [ 0.68, 45.89 ]
Total events: 4 (Enh. recovery protocol), 0 (Standard care)
Heterogeneity: Chi2 = 0.22, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 1.60 (P = 0.11)
Test for subgroup differences: Chi2 = 0.22, df = 1 (P = 0.64), I2 =0.0%
0.005 0.1 1 10 200
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Analysis 2.3. Comparison 2 Enhanced recovery protocol versus standard care (subgroup analysis),
Outcome 3 Serious adverse events (number).
Review: Enhanced recovery protocols for major upper gastrointestinal, liver and pancreatic surgery
Comparison: 2 Enhanced recovery protocol versus standard care (subgroup analysis)
Outcome: 3 Serious adverse events (number)
Study or subgroup log [Rate Ratio] Rate Ratio Weight Rate Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Oesophagectomy
Zhao 2014 -1.1 (1.63) 2.4 % 0.33 [ 0.01, 8.12 ]
Subtotal (95% CI) 2.4 % 0.33 [ 0.01, 8.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
2 Gastrectomy
Kim 2012 1.1 (1.63) 2.4 % 3.00 [ 0.12, 73.31 ]
Lemanu 2013 -0.05 (0.63) 16.4 % 0.95 [ 0.28, 3.27 ]
Subtotal (95% CI) 18.8 % 1.10 [ 0.35, 3.49 ]
Heterogeneity: Chi2 = 0.43, df = 1 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.17 (P = 0.87)
3 Liver surgery
Jones 2013 -0.46 (0.43) 35.2 % 0.63 [ 0.27, 1.47 ]
Lu 2014 2.13 (1.51) 2.9 % 8.41 [ 0.44, 162.32 ]
Ni 2013 -0.08 (0.4) 40.7 % 0.92 [ 0.42, 2.02 ]
Subtotal (95% CI) 78.7 % 0.84 [ 0.48, 1.48 ]
Heterogeneity: Chi2 = 2.83, df = 2 (P = 0.24); I2 =29%
Test for overall effect: Z = 0.59 (P = 0.55)
Total (95% CI) 100.0 % 0.87 [ 0.53, 1.43 ]
Heterogeneity: Chi2 = 3.78, df = 5 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 0.56 (P = 0.58)
Test for subgroup differences: Chi2 = 0.52, df = 2 (P = 0.77), I2 =0.0%
0.005 0.1 1 10 200
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Analysis 2.4. Comparison 2 Enhanced recovery protocol versus standard care (subgroup analysis),
Outcome 4 Health-related quality of life.
Review: Enhanced recovery protocols for major upper gastrointestinal, liver and pancreatic surgery
Comparison: 2 Enhanced recovery protocol versus standard care (subgroup analysis)
Outcome: 4 Health-related quality of life
Study or subgroup
Enh.
recovery
protocol Standard care
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Oesophagectomy
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Gastrectomy
Kim 2012 22 8.9 (2.46) 22 9.28 (2.4) 18.2 % -0.15 [ -0.75, 0.44 ]
Lemanu 2013 40 80.5 (10.2) 38 80.1 (10.1) 24.5 % 0.04 [ -0.41, 0.48 ]
Subtotal (95% CI) 62 60 42.7 % -0.03 [ -0.39, 0.32 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.26, df = 1 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 0.17 (P = 0.87)
3 Liver surgery
Jones 2013 46 37.2 (2.4) 45 35.6 (2.4) 25.6 % 0.66 [ 0.24, 1.08 ]
Ni 2013 80 101.2 (13) 80 93.4 (21.4) 31.6 % 0.44 [ 0.12, 0.75 ]
Subtotal (95% CI) 126 125 57.3 % 0.52 [ 0.27, 0.77 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.69, df = 1 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 4.03 (P = 0.000056)
Total (95% CI) 188 185 100.0 % 0.29 [ -0.04, 0.62 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 7.03, df = 3 (P = 0.07); I2 =57%
Test for overall effect: Z = 1.73 (P = 0.084)
Test for subgroup differences: Chi2 = 6.08, df = 1 (P = 0.01), I2 =84%
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Analysis 3.1. Comparison 3 Enhanced recovery protocol versus standard care (sensitivity analysis),
Outcome 1 Health-related quality of life.
Review: Enhanced recovery protocols for major upper gastrointestinal, liver and pancreatic surgery
Comparison: 3 Enhanced recovery protocol versus standard care (sensitivity analysis)
Outcome: 1 Health-related quality of life
Study or subgroup
Enh.
recovery
protocol Standard care
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Kim 2012 22 8.9 (2.46) 22 9.28 (2.4) 23.5 % -0.15 [ -0.75, 0.44 ]
Lemanu 2013 40 80.5 (10.2) 38 80.1 (10.1) 32.7 % 0.04 [ -0.41, 0.48 ]
Ni 2013 80 101.2 (13) 80 93.4 (21.4) 43.8 % 0.44 [ 0.12, 0.75 ]
Total (95% CI) 142 140 100.0 % 0.17 [ -0.19, 0.53 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 4.02, df = 2 (P = 0.13); I2 =50%
Test for overall effect: Z = 0.93 (P = 0.35)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 Enhanced recovery protocol versus standard care (sensitivity analysis),
Outcome 2 Length of hospital stay.
Review: Enhanced recovery protocols for major upper gastrointestinal, liver and pancreatic surgery
Comparison: 3 Enhanced recovery protocol versus standard care (sensitivity analysis)
Outcome: 2 Length of hospital stay
Study or subgroup
Enh.
recovery
protocol Standard care
Mean
Difference Weight
Mean
Difference
N Mean(SD)[days] N Mean(SD)[days] IV,Fixed,95% CI IV,Fixed,95% CI
Kim 2012 22 5.36 (1.46) 22 7.95 (1.98) 36.2 % -2.59 [ -3.62, -1.56 ]
Liu 2010 33 6.2 (1.9) 30 9.8 (2.8) 26.8 % -3.60 [ -4.79, -2.41 ]
Ni 2013 80 6.9 (2.8) 80 8 (3.7) 37.0 % -1.10 [ -2.12, -0.08 ]
Total (95% CI) 135 132 100.0 % -2.31 [ -2.93, -1.69 ]
Heterogeneity: Chi2 = 10.21, df = 2 (P = 0.01); I2 =80%
Test for overall effect: Z = 7.32 (P < 0.00001)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
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Analysis 3.3. Comparison 3 Enhanced recovery protocol versus standard care (sensitivity analysis),
Outcome 3 Costs.
Review: Enhanced recovery protocols for major upper gastrointestinal, liver and pancreatic surgery
Comparison: 3 Enhanced recovery protocol versus standard care (sensitivity analysis)
Outcome: 3 Costs
Study or subgroup
Enh.
recovery
protocol Standard care
Mean
Difference Weight
Mean
Difference
N
Mean(SD)[,000
USD] N
Mean(SD)[,000
USD] IV,Fixed,95% CI IV,Fixed,95% CI
Kim 2012 22 7.4543 (0.7058) 22 7.77 (0.9342) 19.2 % -0.32 [ -0.81, 0.17 ]
Lemanu 2013 40 11.127 (9.819) 38 11.67 (10.7175) 0.2 % -0.55 [ -5.12, 4.02 ]
Wang 2010 4.354292 (0.585437) 45 47 5.02 (0.582165) 80.6 % -0.67 [ -0.91, -0.43 ]
Total (95% CI) 107 107 100.0 % -0.60 [ -0.81, -0.39 ]
Heterogeneity: Chi2 = 1.58, df = 2 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 5.48 (P < 0.00001)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours enh. rec. prot. Favours standard care
A D D I T I O N A L T A B L E S
Table 1. Participants, elements of enhanced recovery protocol and outcomes reported in included trials
Study name Surgery Preoperative
education
Pain relief
protocol
Early mobili-
sation proto-
col
Nutritional
protocol
Growth fac-
tors
Outcomes re-
ported
Barlow 2011 Major upper
gastrointesti-
nal surgery
(oesophagec-
tomy, gastrec-
tomy and pan-
createctomy)
No No No Yes No 1. Short-
term
mortality
2. Serious
adverse events
3. Mild
adverse events
4. Length
of hospital
stay
Jones 2013 Open liver
surgery
Yes No Yes Yes No 1. Short-
term
mortality
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Table 1. Participants, elements of enhanced recovery protocol and outcomes reported in included trials (Continued)
2. Serious
adverse events
3. Health-
related quality
of life
4. Mild
adverse events
5. Length
of hospital
stay
6. Readmissions
Kim 2012 Laparoscopic
distal gastrec-
tomy
Yes Yes Yes Yes No 1. Short-
term
mortality
2. Serious
adverse events
3. Health-
related quality
of life
4. Mild
adverse events
5. Length
of hospital
stay
6. Readmissions
7. Costs
Lemanu 2013 Laparoscopic
sleeve gastrec-
tomy
Yes Yes Yes Yes No 1. Serious
adverse events
2. Health-
related quality
of life
3. Mild
adverse events
4. Length
of hospital
stay
5. Readmissions
6. Costs
Liu 2010 Gastrectomy Yes Yes Yes Yes No 1. Short-
term
mortality
2. Serious
adverse events
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Table 1. Participants, elements of enhanced recovery protocol and outcomes reported in included trials (Continued)
3. Mild
adverse events
4. Length
of hospital
stay
5. Readmissions
Lu 2014 Liver surgery No No Yes Yes No 1. Short-
term
mortality
2. Serious
adverse events
3. Mild
adverse events
4. Length
of hospital
stay
5. Readmissions
Miyachi 2013 Gastrectomy No No No No Yes None of the
out-
comes of in-
terest were re-
ported
Ni 2013 Partial liver re-
section
Yes Yes Yes Yes No 1. Short-
term
mortality
2. Serious
adverse events
3. Health-
related quality
of life
4. Mild
adverse events
5. Length
of hospital
stay
Wang 2010 Gastrectomy Yes Yes Ys Yes No 1. Short-
term
mortality
2. Mild
adverse events
3. Length
of hospital
stay
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Table 1. Participants, elements of enhanced recovery protocol and outcomes reported in included trials (Continued)
4. Readmissions
5. Costs
Zhao 2014 Oesophagec-
tomy
Yes Yes N No No 1. Serious
adverse events
2. Mild
adverse events
3. Length
of hospital
stay
4. Readmissions
5. Costs
The table shows the surgeries that the participants underwent, the elements of enhanced recovery protocol that were different between
the intervention and control, and the outcomes reported in the trials.
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
((enhanced near/5 recovery) or (fast-track near/5 recovery) or (fast-track near/5 rehabilitation) or ERAS)
Appendix 2. MEDLINE search strategy
1. ((enhanced adj5 recovery) or (fast-track adj5 recovery) or (fast-track adj5 rehabilitation) or ERAS).mp.
2. randomized controlled trial.pt.
3. controlled clinical trial.pt.
4. randomized.ab.
5. placebo.ab.
6. drug therapy.fs.
7. randomly.ab.
8. trial.ab.
9. groups.ab.
10. 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9
11. exp animals/ not humans.sh.
12. 10 not 11
13. 1 and 12
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Appendix 3. EMBASE search strategy
1. ((enhanced adj5 recovery) or (fast-track adj5 recovery) or (fast-track adj5 rehabilitation) or ERAS).mp.
2. Clinical trial/
3. Randomized controlled trial/
4. Randomization/
5. Single-Blind Method/
6. Double-Blind Method/
7. Cross-Over Studies/
8. Random Allocation/
9. Placebo/
10. Randomi?ed controlled trial$.tw.
11. Rct.tw.
12. Random allocation.tw.
13. Randomly allocated.tw.
14. Allocated randomly.tw.
15. (allocated adj2 random).tw.
16. Single blind$.tw.
17. Double blind$.tw.
18. ((treble or triple) adj blind$).tw.
19. Placebo$.tw.
20. Prospective study/
21. or/2-20
22. Case study/
23. Case report.tw.
24. Abstract report/ or letter/
25. or/22-24
26. 21 not 25
27. 1 and 26
Appendix 4. Science Citation Index search strategy
# 1 TS=((enhanced near/5 recovery) or (fast-track near/5 recovery) or (fast-track near/5 rehabilitation) or ERAS)
# 2 TS=(surgery OR surgeries OR surgical OR operation OR operations OR procedure OR procedures)
# 3 TS=(random* OR rct* OR crossover OR masked OR blind* OR placebo* OR meta-analysis OR systematic review* OR meta-
analys*)
# 4 #3 AND #2 AND #1
Appendix 5. ClinicalTrials.gov search strategy
Four searches were performed.
1. Interventional Studies | enhanced recovery | Phase 2, 3, 4
2. Interventional Studies | fast-track recovery | Phase 2, 3, 4
3. Interventional Studies | fast-track rehabilitation | Phase 2, 3, 4
4. Interventional Studies | surgery | ERAS | Phase 2, 3, 4
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Appendix 6. WHO ICTRP search strategy
Enhanced recovery or fast-track recovery or fast-track rehabilitation or ERAS
WH A T ’ S N E W
Last assessed as up-to-date: 26 March 2015.
Date Event Description
2 February 2016 Amended Amendment to External Souces of Support statement.
C O N T R I B U T I O N S O F A U T H O R S
Conceiving of the review: KG
Designing the review: KG
Co-ordinating the review: KG
Designing search strategies: KG
Data extraction: GB-S, AB, KG
Data analysis: KG
Writing the review: KG, GBS
Providing critical comments on the review: AB, BRD
Securing funding for the review: KG, BRD
Performing previous work that served as the foundation of the current study: KG
D E C L A R A T I O N S O F I N T E R E S T
This report comprises independent research funded by the National Institute for Health Research (NIHR) Cochrane Programme
Grants, 13/89/03 (Evidence-based diagnosis and management of upper digestive, hepato-biliary and pancreatic disorders). The views
expressed in this publication are those of the review author(s) and are not necessarily those of the National Health Service (NHS), the
NIHR or the Department of Health.
GB-S: none known.
AB: none known.
BD: none known.
KG: none known.
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S O U R C E S O F S U P P O R T
Internal sources
• University College London, UK.
External sources
• National Institute for Health Research, UK.
This project was supported by the National Institute for Health Research, via Cochrane Programme Grant to the CHBG and UGPD
groups. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic
Reviews Programme, NIHR, NHS or the Department of Health.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Although we did not find multi-arm trials, if we find multi-arm trials in future, we will present the analysis by pooling the intervention
groups and comparing it with control as the main analysis. Comparing each intervention with a split control group to avoid double
counting will be presented as sensitivity analysis. This is following the recommendation of a statistician.
Different methods of dealing with multi-arm trials were planned as a subgroup analysis; however, this has been moved to the sensitivity
analysis section as this was an error in the protocol.
The time period for health-related quality of life was revised from four weeks to three months to include any time until three months.
This is because none of the trials reported health-related quality of life beyond four weeks.
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